https://trial.medpath.com/news/xbb-1-5-likely-resistant-to-evusheld-fda-says 2023-01-09T16:00:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/xbb-1-5-likely-resistant-to-evusheld-fda-says 2023-01-09T16:00:27+00:00 weekly 0.7 https://trial.medpath.com/news/14-breakthrough-drugs-poised-for-blockbuster-status-by-2027-clarivate-analysis 2023-01-09T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/14-breakthrough-drugs-poised-for-blockbuster-status-by-2027-clarivate-analysis 2023-01-09T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/real-world-weight-loss-effectiveness-of-glp-1-agonists-in-type-2-diabetes-patients 2023-01-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/real-world-weight-loss-effectiveness-of-glp-1-agonists-in-type-2-diabetes-patients 2023-01-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/syros-pharmaceuticals-inc-nasdaq-syrs-q1-2023-earnings-call-transcript 2023-01-08T17:01:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/syros-pharmaceuticals-inc-nasdaq-syrs-q1-2023-earnings-call-transcript 2023-01-08T17:01:23+00:00 weekly 0.7 https://trial.medpath.com/news/editas-medicine-inc-nasdaq-edit-q4-2022-earnings-call-transcript 2023-01-08T13:01:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/editas-medicine-inc-nasdaq-edit-q4-2022-earnings-call-transcript 2023-01-08T13:01:57+00:00 weekly 0.7 https://trial.medpath.com/news/aldeyra-therapeutics-inc-nasdaq-aldx-q4-2022-earnings-call-transcript 2023-01-08T12:53:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aldeyra-therapeutics-inc-nasdaq-aldx-q4-2022-earnings-call-transcript 2023-01-08T12:53:45+00:00 weekly 0.7 https://trial.medpath.com/news/fda-pulls-eua-granted-to-astrazeneca-s-azn-evusheld 2023-01-08T12:33:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-pulls-eua-granted-to-astrazeneca-s-azn-evusheld 2023-01-08T12:33:52+00:00 weekly 0.7 https://trial.medpath.com/news/geron-corporation-nasdaq-gern-q4-2022-earnings-call-transcript 2023-01-08T10:55:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/geron-corporation-nasdaq-gern-q4-2022-earnings-call-transcript 2023-01-08T10:55:43+00:00 weekly 0.7 https://trial.medpath.com/news/car-t-cell-therapy-reaches-beyond-cancer-penn-bioengineering-blog 2023-01-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/car-t-cell-therapy-reaches-beyond-cancer-penn-bioengineering-blog 2023-01-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/alzheimers-drug-lecanemab-receives-accelerated-approval-amid-safety-concerns-cnn 2023-01-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alzheimers-drug-lecanemab-receives-accelerated-approval-amid-safety-concerns-cnn 2023-01-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/combomatch-will-test-new-combinations-of-cancer-drugs-nci 2023-01-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/combomatch-will-test-new-combinations-of-cancer-drugs-nci 2023-01-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/veeva-experts-predict-data-driven-transformation-in-life-sciences-r-d-for-2023 2023-01-05T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/veeva-experts-predict-data-driven-transformation-in-life-sciences-r-d-for-2023 2023-01-05T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cilta-cel-garners-more-positive-data-in-early-and-late-relapsed 2023-01-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cilta-cel-garners-more-positive-data-in-early-and-late-relapsed 2023-01-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/bioengineered-probiotic-bacteria-could-replace-injections-for-rheumatoid-arthritis-treatment 2023-01-04T18:55:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bioengineered-probiotic-bacteria-could-replace-injections-for-rheumatoid-arthritis-treatment 2023-01-04T18:55:45+00:00 weekly 0.7 https://trial.medpath.com/news/first-made-in-singapore-antibody-drug-conjugate-adc-approved 2023-01-04T03:10:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-made-in-singapore-antibody-drug-conjugate-adc-approved 2023-01-04T03:10:36+00:00 weekly 0.7 https://trial.medpath.com/news/european-health-data-space-to-transform-pharmaceutical-research-access-by-2025 2023-01-03T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/european-health-data-space-to-transform-pharmaceutical-research-access-by-2025 2023-01-03T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/bdr-pharmaceutical-launches-first-generic-apalutamide-in-india-for-prostate-cancer-treatment 2023-01-03T13:11:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bdr-pharmaceutical-launches-first-generic-apalutamide-in-india-for-prostate-cancer-treatment 2023-01-03T13:11:53+00:00 weekly 0.7 https://trial.medpath.com/news/innovative-clinical-trial-designs-for-glioblastoma-a-new-horizon 2023-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/innovative-clinical-trial-designs-for-glioblastoma-a-new-horizon 2023-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-and-molecular-effects-of-oral-ccr4-antagonist 2023-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-and-molecular-effects-of-oral-ccr4-antagonist 2023-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/efficacy-and-safety-of-inebilizumab-in-igg4-related-disease-pubmed 2023-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/efficacy-and-safety-of-inebilizumab-in-igg4-related-disease-pubmed 2023-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/clover-biopharmaceuticals-advances-rsv-vaccine-scb-1019-with-u-s-ind-clearance-for-revaccination-study 2023-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clover-biopharmaceuticals-advances-rsv-vaccine-scb-1019-with-u-s-ind-clearance-for-revaccination-study 2023-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/gene-therapy-for-hemophilia-a-new-horizon-in-treatment 2022-12-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gene-therapy-for-hemophilia-a-new-horizon-in-treatment 2022-12-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a-good-use-of-time-providing-evidence-for-how-effort-is-invested-in 2022-12-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-good-use-of-time-providing-evidence-for-how-effort-is-invested-in 2022-12-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/emergency-use-authorization-eua-revoked-for 2022-12-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/emergency-use-authorization-eua-revoked-for 2022-12-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/lecanemab-in-patients-with-early-alzheimer-s-disease 2022-12-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lecanemab-in-patients-with-early-alzheimer-s-disease 2022-12-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/boehringer-ingelheim-and-click-therapeutics-expand-digital-therapeutics-alliance-for-schizophrenia-in-460m-deal 2022-12-19T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/boehringer-ingelheim-and-click-therapeutics-expand-digital-therapeutics-alliance-for-schizophrenia-in-460m-deal 2022-12-19T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/eagle-pharmaceuticals-receives-fda-approval-for-additional-indication-for-pemfexy-r-in-combination-with-pembrolizumab-and-platinum-chemotherapy 2022-12-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eagle-pharmaceuticals-receives-fda-approval-for-additional-indication-for-pemfexy-r-in-combination-with-pembrolizumab-and-platinum-chemotherapy 2022-12-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/vergent-bioscience-completes-enrollment-in-phase-2-visualize-trial 2022-12-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vergent-bioscience-completes-enrollment-in-phase-2-visualize-trial 2022-12-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-nadofaragene-firadenovec-for-high-risk-non-muscle-invasive-bladder-cancer 2022-12-16T20:56:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-nadofaragene-firadenovec-for-high-risk-non-muscle-invasive-bladder-cancer 2022-12-16T20:56:59+00:00 weekly 0.7 https://trial.medpath.com/news/renovorx-announces-acceptance-of-four-clinical-data-abstracts-at-the-2023-asco-gastrointestinal-cancers-symposium 2022-12-15T12:30:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/renovorx-announces-acceptance-of-four-clinical-data-abstracts-at-the-2023-asco-gastrointestinal-cancers-symposium 2022-12-15T12:30:43+00:00 weekly 0.7 https://trial.medpath.com/news/iterum-therapeutics-announces-issuance-of-allowance-for-a-u-s-patent-covering-oral-sulopenem 2022-12-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/iterum-therapeutics-announces-issuance-of-allowance-for-a-u-s-patent-covering-oral-sulopenem 2022-12-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/nhs-innovation-commission-charts-path-for-uk-healthcare-transformation-and-life-sciences-growth 2022-12-14T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nhs-innovation-commission-charts-path-for-uk-healthcare-transformation-and-life-sciences-growth 2022-12-14T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/challenges-and-advances-in-alzheimer-s-and-parkinson-s-disease-research 2022-12-13T16:33:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/challenges-and-advances-in-alzheimer-s-and-parkinson-s-disease-research 2022-12-13T16:33:49+00:00 weekly 0.7 https://trial.medpath.com/news/rsv-emerges-as-hidden-threat-to-elderly-population-causing-8000-annual-deaths-in-uk 2022-12-13T09:23:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rsv-emerges-as-hidden-threat-to-elderly-population-causing-8000-annual-deaths-in-uk 2022-12-13T09:23:00+00:00 weekly 0.7 https://trial.medpath.com/news/biogen-advances-digital-health-innovation-in-neurology-through-four-pillar-strategy 2022-12-11T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biogen-advances-digital-health-innovation-in-neurology-through-four-pillar-strategy 2022-12-11T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/elranatamab-achieves-61-response-rate-in-heavily-pretreated-multiple-myeloma-patients 2022-12-10T23:00:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/elranatamab-achieves-61-response-rate-in-heavily-pretreated-multiple-myeloma-patients 2022-12-10T23:00:37+00:00 weekly 0.7 https://trial.medpath.com/news/agios-presents-updated-pyrukynd-r-mitapivat-data-highlighting-long 2022-12-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/agios-presents-updated-pyrukynd-r-mitapivat-data-highlighting-long 2022-12-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/psilocybin-assisted-therapy-mediates-psycho-social 2022-12-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/psilocybin-assisted-therapy-mediates-psycho-social 2022-12-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/intrabio-completes-over-enrollment-for-pivotal-niemann-pick-disease-type-c-trial-data-expected-q2-2023 2022-12-08T13:30:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/intrabio-completes-over-enrollment-for-pivotal-niemann-pick-disease-type-c-trial-data-expected-q2-2023 2022-12-08T13:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-investigational-iptacopan-provides-clinically-meaningful-increases-in-hemoglobin-levels-in-complement-inhibitor-naive-patients-with-pnh 2022-12-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novartis-investigational-iptacopan-provides-clinically-meaningful-increases-in-hemoglobin-levels-in-complement-inhibitor-naive-patients-with-pnh 2022-12-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/car-t-cell-therapy-shows-promise-despite-significant-safety-challenges-in-clinical-trials 2022-12-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/car-t-cell-therapy-shows-promise-despite-significant-safety-challenges-in-clinical-trials 2022-12-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/uk-life-sciences-council-lacks-transparency-despite-critical-industry-role 2022-12-07T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/uk-life-sciences-council-lacks-transparency-despite-critical-industry-role 2022-12-07T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/yonalink-secures-6m-investment-to-transform-clinical-trial-data-management-with-real-time-streaming-technology 2022-12-05T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/yonalink-secures-6m-investment-to-transform-clinical-trial-data-management-with-real-time-streaming-technology 2022-12-05T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/heparegenix-reports-positive-topline-results-of-its-phase-1-clinical 2022-12-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/heparegenix-reports-positive-topline-results-of-its-phase-1-clinical 2022-12-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/novel-hiv-vaccine-shows-97-antibody-response-rate-in-phase-1-trial 2022-12-01T19:00:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novel-hiv-vaccine-shows-97-antibody-response-rate-in-phase-1-trial 2022-12-01T19:00:54+00:00 weekly 0.7 https://trial.medpath.com/news/ai-powered-analytics-transform-clinical-trial-design-and-enrollment-strategy 2022-12-01T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ai-powered-analytics-transform-clinical-trial-design-and-enrollment-strategy 2022-12-01T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-olutasidenib-for-acute-myeloid-leukemia-subtype 2022-12-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-olutasidenib-for-acute-myeloid-leukemia-subtype 2022-12-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/industry-leaders-push-for-patient-centric-clinical-trials-through-technology-and-community-engagement 2022-11-30T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/industry-leaders-push-for-patient-centric-clinical-trials-through-technology-and-community-engagement 2022-11-30T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/alzheimer-s-drug-lecanemab-hailed-as-momentous 2022-11-30T01:05:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alzheimer-s-drug-lecanemab-hailed-as-momentous 2022-11-30T01:05:39+00:00 weekly 0.7 https://trial.medpath.com/news/experimental-drug-appears-to-slow-progression-of-alzheimers-disease-in-clinical-trial-but-raises-safety-concerns-cnn 2022-11-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/experimental-drug-appears-to-slow-progression-of-alzheimers-disease-in-clinical-trial-but-raises-safety-concerns-cnn 2022-11-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/car-t-cell-therapy-reaches-beyond-cancer-penn-today 2022-11-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/car-t-cell-therapy-reaches-beyond-cancer-penn-today 2022-11-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/roche-withdraws-tecentriq-from-bladder-cancer-market-following-failed-confirmatory-trial 2022-11-29T16:26:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/roche-withdraws-tecentriq-from-bladder-cancer-market-following-failed-confirmatory-trial 2022-11-29T16:26:54+00:00 weekly 0.7 https://trial.medpath.com/news/automation-emerges-as-key-solution-to-pharmaceutical-supply-chain-vulnerabilities 2022-11-27T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/automation-emerges-as-key-solution-to-pharmaceutical-supply-chain-vulnerabilities 2022-11-27T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/new-drug-development-pipeline-shows-promise-for-als-treatment-with-53-candidates-under-investigation 2022-11-27T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-drug-development-pipeline-shows-promise-for-als-treatment-with-53-candidates-under-investigation 2022-11-27T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/mhra-and-nhs-england-fast-track-novel-prostate-cancer-treatment-darolutamide-combination-therapy 2022-11-27T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mhra-and-nhs-england-fast-track-novel-prostate-cancer-treatment-darolutamide-combination-therapy 2022-11-27T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/rare-disease-drug-development-faces-critical-forecasting-challenges-with-only-5-having-approved-treatments 2022-11-24T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rare-disease-drug-development-faces-critical-forecasting-challenges-with-only-5-having-approved-treatments 2022-11-24T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/margetuximab-does-not-surpass-trastuzumab-in-terms-of 2022-11-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/margetuximab-does-not-surpass-trastuzumab-in-terms-of 2022-11-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-teplizumab-first-disease-modifying-drug-for-type-1-diabetes-prevention 2022-11-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-teplizumab-first-disease-modifying-drug-for-type-1-diabetes-prevention 2022-11-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fierce-biotech-fda-wants-confirmatory-trials-to-be-underway-before 2022-11-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fierce-biotech-fda-wants-confirmatory-trials-to-be-underway-before 2022-11-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/raesedo-inc-awarded-3-4m-sttr-grant-to-develop-new-asthma-therapies 2022-11-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/raesedo-inc-awarded-3-4m-sttr-grant-to-develop-new-asthma-therapies 2022-11-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/characteristics-of-measurable-residual-disease-assessment-in-myeloma-a 2022-11-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/characteristics-of-measurable-residual-disease-assessment-in-myeloma-a 2022-11-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/healthcare-investment-landscape-shows-signs-of-stabilization-after-2021-surge-industry-leaders-report-at-lsx-showcase 2022-11-14T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/healthcare-investment-landscape-shows-signs-of-stabilization-after-2021-surge-industry-leaders-report-at-lsx-showcase 2022-11-14T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/roche-s-gantenerumab-fails-to-meet-primary-endpoints-in-phase-3-alzheimer-s-trials 2022-11-14T08:59:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/roche-s-gantenerumab-fails-to-meet-primary-endpoints-in-phase-3-alzheimer-s-trials 2022-11-14T08:59:00+00:00 weekly 0.7 https://trial.medpath.com/news/viridian-announces-positive-data-from-ongoing-phase-1-2-trial-evaluating-vrdn-001-in-patients-with-thyroid-eye-disease-ted 2022-11-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/viridian-announces-positive-data-from-ongoing-phase-1-2-trial-evaluating-vrdn-001-in-patients-with-thyroid-eye-disease-ted 2022-11-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/xeltis-starts-pivotal-clinical-trial-with-first-ever-restorative 2022-11-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/xeltis-starts-pivotal-clinical-trial-with-first-ever-restorative 2022-11-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/paxlovid-may-reduce-risk-of-long-covid-study-suggests 2022-11-09T21:53:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/paxlovid-may-reduce-risk-of-long-covid-study-suggests 2022-11-09T21:53:46+00:00 weekly 0.7 https://trial.medpath.com/news/aquatic-vaccines-current-status-and-future-development-prospects-in-global-aquaculture 2022-11-09T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aquatic-vaccines-current-status-and-future-development-prospects-in-global-aquaculture 2022-11-09T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-regeneron-s-libtayo-combination-for-non-small-cell-lung-cancer-treatment 2022-11-09T12:13:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-regeneron-s-libtayo-combination-for-non-small-cell-lung-cancer-treatment 2022-11-09T12:13:00+00:00 weekly 0.7 https://trial.medpath.com/news/real-world-first-line-treatment-patterns-and-outcomes-for-brafv600e-mutant-metastatic-colorectal-cancer-in-europe 2022-11-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/real-world-first-line-treatment-patterns-and-outcomes-for-brafv600e-mutant-metastatic-colorectal-cancer-in-europe 2022-11-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/impact-of-mrd-status-and-number-of-remissions-on-hsct-outcomes-aml-hub 2022-11-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/impact-of-mrd-status-and-number-of-remissions-on-hsct-outcomes-aml-hub 2022-11-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/baxdrostat-shows-dramatic-blood-pressure-reduction-in-treatment-resistant-hypertension-trial 2022-11-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/baxdrostat-shows-dramatic-blood-pressure-reduction-in-treatment-resistant-hypertension-trial 2022-11-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/top-biotech-stocks-for-q2-2023 2022-11-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/top-biotech-stocks-for-q2-2023 2022-11-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/treasure-data-releases-whitepaper-on-maximizing-data-utilization-in-pharmaceutical-industry 2022-11-03T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/treasure-data-releases-whitepaper-on-maximizing-data-utilization-in-pharmaceutical-industry 2022-11-03T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/moderna-sues-pfizer-and-biontech-over-mrna-covid-19-vaccine-patent-infringement 2022-11-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/moderna-sues-pfizer-and-biontech-over-mrna-covid-19-vaccine-patent-infringement 2022-11-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/sirona-completes-enrollment-a-leap-in-the-dcb-treatment-of 2022-11-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sirona-completes-enrollment-a-leap-in-the-dcb-treatment-of 2022-11-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/stem-cell-strategies-show-promise-for-rebuilding-brain-tissue-in-neurodegenerative-diseases 2022-11-01T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/stem-cell-strategies-show-promise-for-rebuilding-brain-tissue-in-neurodegenerative-diseases 2022-11-01T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/small-business-americus-times-recorder-americus-times-recorder 2022-11-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/small-business-americus-times-recorder-americus-times-recorder 2022-11-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/topical-tranexamic-acid-reduces-blood-loss-in-knee-arthroplasty-study-finds 2022-11-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/topical-tranexamic-acid-reduces-blood-loss-in-knee-arthroplasty-study-finds 2022-11-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/eli-lilly-invests-92-5m-in-purdue-university-to-advance-pharmaceutical-manufacturing-and-research 2022-10-31T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eli-lilly-invests-92-5m-in-purdue-university-to-advance-pharmaceutical-manufacturing-and-research 2022-10-31T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/prospective-open-label-single-arm-single-center-follow-up-study-of 2022-10-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/prospective-open-label-single-arm-single-center-follow-up-study-of 2022-10-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/invitae-study-shows-therapy-informed-by-genetic-testing-reduces-seizures-in-some-patients-with-epilepsy 2022-10-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/invitae-study-shows-therapy-informed-by-genetic-testing-reduces-seizures-in-some-patients-with-epilepsy 2022-10-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/monoclonal-antibody-prevents-malaria-infection-in-african-adults 2022-10-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/monoclonal-antibody-prevents-malaria-infection-in-african-adults 2022-10-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/medical-device-advances-in-the-treatment-of-glioblastoma 2022-10-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/medical-device-advances-in-the-treatment-of-glioblastoma 2022-10-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/genmab-and-abbvie-submit-regulatory-applications-for-epcoritamab-bispecific-antibody-in-relapsed-refractory-b-cell-lymphomas 2022-10-28T12:46:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/genmab-and-abbvie-submit-regulatory-applications-for-epcoritamab-bispecific-antibody-in-relapsed-refractory-b-cell-lymphomas 2022-10-28T12:46:06+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-astrazeneca-s-dual-immunotherapy-combination-for-unresectable-liver-cancer 2022-10-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-astrazeneca-s-dual-immunotherapy-combination-for-unresectable-liver-cancer 2022-10-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/sequana-medical-announces-positive-top-line-results-from 2022-10-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sequana-medical-announces-positive-top-line-results-from 2022-10-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ivermectin-a-drug-once-touted-as-a-covid-treatment-by-conservatives-doesn-t-improve-recovery-much-clinical-trial-finds 2022-10-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ivermectin-a-drug-once-touted-as-a-covid-treatment-by-conservatives-doesn-t-improve-recovery-much-clinical-trial-finds 2022-10-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/f2g-s-olorofim-shows-44-response-rate-in-phase-2b-trial-for-invasive-fungal-infections 2022-10-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/f2g-s-olorofim-shows-44-response-rate-in-phase-2b-trial-for-invasive-fungal-infections 2022-10-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/evotec-receives-2-5m-gates-foundation-grant-for-ipsc-based-teratogenicity-platform 2022-10-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/evotec-receives-2-5m-gates-foundation-grant-for-ipsc-based-teratogenicity-platform 2022-10-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/intraventricular-b7-h3-car-t-cells-for-diffuse-intrinsic 2022-10-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/intraventricular-b7-h3-car-t-cells-for-diffuse-intrinsic 2022-10-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/mereo-biopharma-announces-updated-operating-plan-to-maximize-shareholder-value 2022-10-18T11:06:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mereo-biopharma-announces-updated-operating-plan-to-maximize-shareholder-value 2022-10-18T11:06:14+00:00 weekly 0.7 https://trial.medpath.com/news/nanopharmaceutics-completes-enrollment-in-phase-2-neuroendocrine-tumor-study-combining-triapine-with-lutetium-lu-177-dotatate 2022-10-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nanopharmaceutics-completes-enrollment-in-phase-2-neuroendocrine-tumor-study-combining-triapine-with-lutetium-lu-177-dotatate 2022-10-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/eli-lilly-acquires-akouos-for-610m-to-expand-gene-therapy-portfolio-in-hearing-loss-treatment 2022-10-17T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eli-lilly-acquires-akouos-for-610m-to-expand-gene-therapy-portfolio-in-hearing-loss-treatment 2022-10-17T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/attralus-enrolls-first-subject-in-phase-1-clinical-trial-for-at-02-a-pan-amyloid-removal-therapeutic 2022-10-17T11:06:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/attralus-enrolls-first-subject-in-phase-1-clinical-trial-for-at-02-a-pan-amyloid-removal-therapeutic 2022-10-17T11:06:06+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-rmat-and-fast-track-designations-to-caribou-s-allogeneic-car-t-therapy-cb-010-for-b-cell-lymphoma 2022-10-14T18:00:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-rmat-and-fast-track-designations-to-caribou-s-allogeneic-car-t-therapy-cb-010-for-b-cell-lymphoma 2022-10-14T18:00:39+00:00 weekly 0.7 https://trial.medpath.com/news/neoadjuvant-immunotherapy-shows-promise-in-melanoma-treatment-two-studies-demonstrate-improved-outcomes-with-pre-surgery-approach 2022-10-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neoadjuvant-immunotherapy-shows-promise-in-melanoma-treatment-two-studies-demonstrate-improved-outcomes-with-pre-surgery-approach 2022-10-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/significant-improvement-in-overall-survival-with-adjuvant-olaparib-in-high-risk-early-breast-cancer-patients-with-brca1-2-mutations 2022-10-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/significant-improvement-in-overall-survival-with-adjuvant-olaparib-in-high-risk-early-breast-cancer-patients-with-brca1-2-mutations 2022-10-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/insulin-glargine-and-liraglutide-show-superior-performance-in-large-type-2-diabetes-comparative-trial 2022-10-07T16:08:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/insulin-glargine-and-liraglutide-show-superior-performance-in-large-type-2-diabetes-comparative-trial 2022-10-07T16:08:20+00:00 weekly 0.7 https://trial.medpath.com/news/reproxalap-for-dry-eye-disease-aldeyra-therapeutics-inc 2022-10-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/reproxalap-for-dry-eye-disease-aldeyra-therapeutics-inc 2022-10-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/xeltis-presents-promising-first-in-human-data-on-restorative 2022-10-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/xeltis-presents-promising-first-in-human-data-on-restorative 2022-10-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/uab-research-finds-obesity-drug-can-reduce-the-risk-of-type-2-diabetes 2022-10-06T16:39:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/uab-research-finds-obesity-drug-can-reduce-the-risk-of-type-2-diabetes 2022-10-06T16:39:00+00:00 weekly 0.7 https://trial.medpath.com/news/aerorx-and-hcmed-partner-to-develop-first-nebulized-laba-lama-combination-for-copd-treatment 2022-10-02T21:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aerorx-and-hcmed-partner-to-develop-first-nebulized-laba-lama-combination-for-copd-treatment 2022-10-02T21:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/initial-safety-run-in-results-of-the-phase-3-lotis-5-trial-for-r-r-dlbcl-treatment 2022-10-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/initial-safety-run-in-results-of-the-phase-3-lotis-5-trial-for-r-r-dlbcl-treatment 2022-10-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/mpn-545-surpass-et-ropeginterferon-alfa-2b-p1101-vs-anagrelide-as 2022-10-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mpn-545-surpass-et-ropeginterferon-alfa-2b-p1101-vs-anagrelide-as 2022-10-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/glp-1-receptor-agonists-show-significant-weight-loss-benefits-in-overweight-and-obese-patients 2022-10-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/glp-1-receptor-agonists-show-significant-weight-loss-benefits-in-overweight-and-obese-patients 2022-10-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a-prospective-single-centre-open-label-single-arm-pilot-study-to 2022-10-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-prospective-single-centre-open-label-single-arm-pilot-study-to 2022-10-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-watchdog-report-reveals-one-third-of-accelerated-approval-drugs-lack-confirmatory-trial-data 2022-09-30T04:10:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-watchdog-report-reveals-one-third-of-accelerated-approval-drugs-lack-confirmatory-trial-data 2022-09-30T04:10:00+00:00 weekly 0.7 https://trial.medpath.com/news/alzheimer-s-slowing-drug-labelled-historic 2022-09-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alzheimer-s-slowing-drug-labelled-historic 2022-09-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/photocure-and-karl-storz-launch-advanced-blue-light-cystoscopy-system-in-us-market 2022-09-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/photocure-and-karl-storz-launch-advanced-blue-light-cystoscopy-system-in-us-market 2022-09-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/population-pharmacokinetic-pharmacodynamic-analyses 2022-09-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/population-pharmacokinetic-pharmacodynamic-analyses 2022-09-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/lipocine-pivots-to-cns-disorders-with-oral-neuroactive-steroid-pipeline 2022-09-26T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lipocine-pivots-to-cns-disorders-with-oral-neuroactive-steroid-pipeline 2022-09-26T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cytokine-profile-at-diagnosis-affecting-trough 2022-09-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cytokine-profile-at-diagnosis-affecting-trough 2022-09-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/genetically-modified-herpes-virus-shows-promise-against-advanced-cancers-in-early-trial 2022-09-22T23:01:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/genetically-modified-herpes-virus-shows-promise-against-advanced-cancers-in-early-trial 2022-09-22T23:01:00+00:00 weekly 0.7 https://trial.medpath.com/news/real-world-study-shows-axicabtagene-ciloleucel-outperforms-tisagenlecleucel-in-relapsed-refractory-dlbcl 2022-09-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/real-world-study-shows-axicabtagene-ciloleucel-outperforms-tisagenlecleucel-in-relapsed-refractory-dlbcl 2022-09-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/experts-call-for-reform-in-experimental-treatment-access-balancing-patient-rights-with-sustainable-development 2022-09-17T04:21:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/experts-call-for-reform-in-experimental-treatment-access-balancing-patient-rights-with-sustainable-development 2022-09-17T04:21:54+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-breakthrough-therapy-designation-for-affinity-enhanced-t-cell-therapy-in-synovial-sarcoma 2022-09-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-breakthrough-therapy-designation-for-affinity-enhanced-t-cell-therapy-in-synovial-sarcoma 2022-09-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/adeno-associated-virus-gene-therapy-for-hemophilia-a-new-therapeutic-paradigm 2022-09-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/adeno-associated-virus-gene-therapy-for-hemophilia-a-new-therapeutic-paradigm 2022-09-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/synergia-medical-secures-eur9-million-in-series-b-funding-for-epilepsy-treatment-innovation 2022-09-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/synergia-medical-secures-eur9-million-in-series-b-funding-for-epilepsy-treatment-innovation 2022-09-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-fast-track-designation-to-mersana-therapeutics-xmt-1660-for-triple-negative-breast-cancer-treatment 2022-09-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-fast-track-designation-to-mersana-therapeutics-xmt-1660-for-triple-negative-breast-cancer-treatment 2022-09-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/low-dose-interleukin-2-shows-promise-in-slowing-motor-neurone-disease-progression-in-landmark-mirocals-trial 2022-09-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/low-dose-interleukin-2-shows-promise-in-slowing-motor-neurone-disease-progression-in-landmark-mirocals-trial 2022-09-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/tecvayli-shows-promising-outcomes-in-treating-advanced-multiple-myeloma 2022-09-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tecvayli-shows-promising-outcomes-in-treating-advanced-multiple-myeloma 2022-09-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/entrepreneurial-accelerator-program-eap-portfolio-company-receives-400000-research-grant-from-the-national-cancer-institute-to-study-a-repurposed-drug-in-treatment-of-glioblastoma 2022-09-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/entrepreneurial-accelerator-program-eap-portfolio-company-receives-400000-research-grant-from-the-national-cancer-institute-to-study-a-repurposed-drug-in-treatment-of-glioblastoma 2022-09-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ashvattha-therapeutics-advances-in-medical-research-and-clinical-trials 2022-09-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ashvattha-therapeutics-advances-in-medical-research-and-clinical-trials 2022-09-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-priority-review-for-trodelvy-in-hr-her2-metastatic-breast-cancer-following-positive-survival-data 2022-09-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-priority-review-for-trodelvy-in-hr-her2-metastatic-breast-cancer-following-positive-survival-data 2022-09-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/continuous-circadian-intracerebroventricular 2022-09-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/continuous-circadian-intracerebroventricular 2022-09-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fluoguide-receives-approval-for-phase-ii-trial-in-head-and-neck-cancer 2022-09-06T11:48:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fluoguide-receives-approval-for-phase-ii-trial-in-head-and-neck-cancer 2022-09-06T11:48:12+00:00 weekly 0.7 https://trial.medpath.com/news/neoadjuvant-immunochemotherapy-shows-promise-for-early-stage-small-cell-lung-cancer-surgery 2022-09-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neoadjuvant-immunochemotherapy-shows-promise-for-early-stage-small-cell-lung-cancer-surgery 2022-09-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-platform-trials-for-coronavirus-covid-19-treatments-gov-uk 2022-09-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-platform-trials-for-coronavirus-covid-19-treatments-gov-uk 2022-09-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/standardizing-eligibility-criteria-a-new-approach-to 2022-09-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/standardizing-eligibility-criteria-a-new-approach-to 2022-09-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/brodalumab-improves-health-related-quality-of-life-in-psoriasis-patients-itching-remains-a-challenge 2022-09-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/brodalumab-improves-health-related-quality-of-life-in-psoriasis-patients-itching-remains-a-challenge 2022-09-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-scemblix-r-with-novel-mechanism-of-action-approved-by 2022-08-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novartis-scemblix-r-with-novel-mechanism-of-action-approved-by 2022-08-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/psychedelic-clinical-trials-enter-new-era-key-protocol-design-and-safety-considerations-emerge 2022-08-28T21:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/psychedelic-clinical-trials-enter-new-era-key-protocol-design-and-safety-considerations-emerge 2022-08-28T21:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/impact-of-teclistamab-and-talquetamab-on-soluble-bcma-levels-in-multiple-myeloma-treatment 2022-08-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/impact-of-teclistamab-and-talquetamab-on-soluble-bcma-levels-in-multiple-myeloma-treatment 2022-08-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/bayer-submits-application-in-china-for-additional-indication 2022-08-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bayer-submits-application-in-china-for-additional-indication 2022-08-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/k36-therapeutics-receives-fda-clearance-for-first-in-class-multiple-myeloma-drug-ktx-1001 2022-08-23T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/k36-therapeutics-receives-fda-clearance-for-first-in-class-multiple-myeloma-drug-ktx-1001 2022-08-23T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/next-generation-rna-technologies-promise-longer-lasting-therapeutics-beyond-mrna 2022-08-22T21:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/next-generation-rna-technologies-promise-longer-lasting-therapeutics-beyond-mrna 2022-08-22T21:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/eye-on-pharma-celltrion-aims-for-adalimumab-interchangeability-phase 2022-08-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eye-on-pharma-celltrion-aims-for-adalimumab-interchangeability-phase 2022-08-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cambridge-researchers-successfully-convert-kidney-blood-types-to-universal-o-potentially-expanding-transplant-access 2022-08-15T07:02:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cambridge-researchers-successfully-convert-kidney-blood-types-to-universal-o-potentially-expanding-transplant-access 2022-08-15T07:02:31+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-decitabine-and-cedazuridine-tablets-for-myelodysplastic-syndromes 2022-08-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-decitabine-and-cedazuridine-tablets-for-myelodysplastic-syndromes 2022-08-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/positive-results-from-b-clear-phase-iib-trial-for-bepirovirsen-in-chronic-hepatitis-b-treatment 2022-08-11T14:58:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/positive-results-from-b-clear-phase-iib-trial-for-bepirovirsen-in-chronic-hepatitis-b-treatment 2022-08-11T14:58:15+00:00 weekly 0.7 https://trial.medpath.com/news/as-billionaires-race-to-fund-anti-aging-projects-a-much-discussed-trial-goes-overlooked 2022-08-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/as-billionaires-race-to-fund-anti-aging-projects-a-much-discussed-trial-goes-overlooked 2022-08-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a-lyme-disease-vaccine-is-in-its-final-clinical-trial-npr 2022-08-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-lyme-disease-vaccine-is-in-its-final-clinical-trial-npr 2022-08-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/tagrisso-plus-savolitinib-shows-promising-49-response-rate-in-egfr-mutated-lung-cancer-with-met-resistance 2022-08-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tagrisso-plus-savolitinib-shows-promising-49-response-rate-in-egfr-mutated-lung-cancer-with-met-resistance 2022-08-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/nek7-emerges-as-promising-inflammasome-target-despite-novartis-study-raising-questions-about-universal-requirement 2022-08-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nek7-emerges-as-promising-inflammasome-target-despite-novartis-study-raising-questions-about-universal-requirement 2022-08-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/bellaseno-initiates-clinical-trials-for-resorbable-breast-and-chest-implants 2022-08-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bellaseno-initiates-clinical-trials-for-resorbable-breast-and-chest-implants 2022-08-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/efficacy-and-safety-of-anlotinib-in-extensive-stage-small-cell-lung-cancer 2022-08-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/efficacy-and-safety-of-anlotinib-in-extensive-stage-small-cell-lung-cancer 2022-08-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-s-accelerated-approval-program-shows-strong-performance-despite-recent-criticisms-analysis-reveals 2022-07-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-s-accelerated-approval-program-shows-strong-performance-despite-recent-criticisms-analysis-reveals 2022-07-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/doxypep-using-antibiotics-to-prevent-stis 2022-07-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/doxypep-using-antibiotics-to-prevent-stis 2022-07-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/oral-carbapenems-promise-peril-and-pushbacks 2022-07-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/oral-carbapenems-promise-peril-and-pushbacks 2022-07-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/our-dna-could-affect-the-potency-of-psychedelics-in-the-brain 2022-07-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/our-dna-could-affect-the-potency-of-psychedelics-in-the-brain 2022-07-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/with-merck-known-as-msd-outside 2022-07-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/with-merck-known-as-msd-outside 2022-07-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/senate-finance-committee-revises-medicare-drug-negotiation-policy-removing-automatic-inclusion-of-insulins 2022-07-25T17:26:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/senate-finance-committee-revises-medicare-drug-negotiation-policy-removing-automatic-inclusion-of-insulins 2022-07-25T17:26:30+00:00 weekly 0.7 https://trial.medpath.com/news/sling-therapeutics-initiates-enrollment-in-phase-2b-lids-clinical-trial-for-thyroid-eye-disease 2022-07-25T12:00:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sling-therapeutics-initiates-enrollment-in-phase-2b-lids-clinical-trial-for-thyroid-eye-disease 2022-07-25T12:00:40+00:00 weekly 0.7 https://trial.medpath.com/news/test-reliability-and-compliance-to-a-twelve-month-visual 2022-07-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/test-reliability-and-compliance-to-a-twelve-month-visual 2022-07-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/spectral-medical-provides-update-on-tigris-clinical-trial-biospace 2022-07-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/spectral-medical-provides-update-on-tigris-clinical-trial-biospace 2022-07-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cardiofocus-advances-in-pulsed-field-ablation-technology-for-atrial-fibrillation-treatment 2022-07-19T10:30:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cardiofocus-advances-in-pulsed-field-ablation-technology-for-atrial-fibrillation-treatment 2022-07-19T10:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/nhs-england-approves-two-life-extending-breast-cancer-drugs-after-initial-rejection 2022-07-14T05:01:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nhs-england-approves-two-life-extending-breast-cancer-drugs-after-initial-rejection 2022-07-14T05:01:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-authorizes-novavax-s-protein-based-covid-19-vaccine-for-us-adults 2022-07-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-authorizes-novavax-s-protein-based-covid-19-vaccine-for-us-adults 2022-07-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-orphan-drug-and-fast-track-designations-to-cv-01-for-recurrent-glioblastoma-treatment 2022-07-13T15:03:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-orphan-drug-and-fast-track-designations-to-cv-01-for-recurrent-glioblastoma-treatment 2022-07-13T15:03:42+00:00 weekly 0.7 https://trial.medpath.com/news/a-phase-ii-study-of-retifanlimab-incmga00012-in-patients 2022-07-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-phase-ii-study-of-retifanlimab-incmga00012-in-patients 2022-07-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/sequana-medical-announces-unconditional-ide-approval-from-u-s-fda-to 2022-07-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sequana-medical-announces-unconditional-ide-approval-from-u-s-fda-to 2022-07-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/sunvozertinib-shows-promising-37-5-response-rate-in-phase-i-trial-for-egfr-exon-20-insertion-nsclc 2022-07-06T13:10:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sunvozertinib-shows-promising-37-5-response-rate-in-phase-i-trial-for-egfr-exon-20-insertion-nsclc 2022-07-06T13:10:00+00:00 weekly 0.7 https://trial.medpath.com/news/the-fda-accepts-bla-and-grants-priority-review-for-lecanemab-for 2022-07-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-fda-accepts-bla-and-grants-priority-review-for-lecanemab-for 2022-07-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-belumosudil-for-chronic-graft-versus-host-disease-treatment 2022-07-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-belumosudil-for-chronic-graft-versus-host-disease-treatment 2022-07-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/margetuximab-versus-trastuzumab-in-patients-with 2022-07-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/margetuximab-versus-trastuzumab-in-patients-with 2022-07-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/first-patient-dosed-in-groundbreaking-stem-cell-therapy-trial-for-drug-resistant-epilepsy-shows-dramatic-seizure-reduction 2022-06-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-patient-dosed-in-groundbreaking-stem-cell-therapy-trial-for-drug-resistant-epilepsy-shows-dramatic-seizure-reduction 2022-06-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-nvs-gets-positive-chmp-opinion-for-scemblix-in-cml 2022-06-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novartis-nvs-gets-positive-chmp-opinion-for-scemblix-in-cml 2022-06-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ruxolitinib-plus-steroids-shows-superior-early-response-in-first-line-acute-gvhd-treatment 2022-06-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ruxolitinib-plus-steroids-shows-superior-early-response-in-first-line-acute-gvhd-treatment 2022-06-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/novel-antibody-drug-conjugate-l-dos47-shows-safety-profile-in-phase-i-ii-nsclc-trial 2022-06-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novel-antibody-drug-conjugate-l-dos47-shows-safety-profile-in-phase-i-ii-nsclc-trial 2022-06-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/car-t-therapy-demonstrates-superior-efficacy-over-bispecific-antibodies-in-relapsed-refractory-follicular-lymphoma 2022-06-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/car-t-therapy-demonstrates-superior-efficacy-over-bispecific-antibodies-in-relapsed-refractory-follicular-lymphoma 2022-06-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/comprehensive-vaers-analysis-confirms-safety-profile-of-pneumococcal-vaccines-across-multiple-formulations 2022-06-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/comprehensive-vaers-analysis-confirms-safety-profile-of-pneumococcal-vaccines-across-multiple-formulations 2022-06-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/hong-kong-study-reveals-comparable-safety-profiles-between-coronavac-and-bnt162b2-covid-19-vaccines 2022-06-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hong-kong-study-reveals-comparable-safety-profiles-between-coronavac-and-bnt162b2-covid-19-vaccines 2022-06-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-receives-positive-chmp-opinion-for-scemblix-r-a-novel 2022-06-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novartis-receives-positive-chmp-opinion-for-scemblix-r-a-novel 2022-06-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-gives-approval-for-novartis-tafinlar-mekinist-broadens-braf-mek-cancer-combo-use 2022-06-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-gives-approval-for-novartis-tafinlar-mekinist-broadens-braf-mek-cancer-combo-use 2022-06-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/penn-researchers-earn-nearly-1-billion-from-mrna-covid-vaccine-technology-royalties 2022-06-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/penn-researchers-earn-nearly-1-billion-from-mrna-covid-vaccine-technology-royalties 2022-06-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/real-world-outcomes-with-fedratinib-in-myelofibrosis-patients-post-ruxolitinib-discontinuation 2022-06-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/real-world-outcomes-with-fedratinib-in-myelofibrosis-patients-post-ruxolitinib-discontinuation 2022-06-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/study-on-brentuximab-vedotin-combination-therapy-for-relapsed-refractory-dlbcl-shows-promising-results 2022-06-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-on-brentuximab-vedotin-combination-therapy-for-relapsed-refractory-dlbcl-shows-promising-results 2022-06-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-gets-accelerated-fda-approval-for-dabrafenib-trametinib 2022-06-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novartis-gets-accelerated-fda-approval-for-dabrafenib-trametinib 2022-06-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/advances-in-the-clinical-development-of-oncolytic-viruses 2022-06-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/advances-in-the-clinical-development-of-oncolytic-viruses 2022-06-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/valbiotis-announces-major-success-in-phase-ii-heart-clinical-study-for-totum-070 2022-06-13T16:36:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/valbiotis-announces-major-success-in-phase-ii-heart-clinical-study-for-totum-070 2022-06-13T16:36:09+00:00 weekly 0.7 https://trial.medpath.com/news/sling-therapeutics-launches-with-35m-series-a-financing-to-develop-oral-small-molecule-for-thyroid-eye-disease 2022-06-13T08:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sling-therapeutics-launches-with-35m-series-a-financing-to-develop-oral-small-molecule-for-thyroid-eye-disease 2022-06-13T08:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/lead-pharma-and-oxeltis-secure-eur800k-grant-to-develop-first-in-class-dlbcl-therapy 2022-06-09T10:50:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lead-pharma-and-oxeltis-secure-eur800k-grant-to-develop-first-in-class-dlbcl-therapy 2022-06-09T10:50:10+00:00 weekly 0.7 https://trial.medpath.com/news/bayer-s-bluerock-therapeutics-expands-to-europe-with-new-berlin-site 2022-06-09T01:22:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bayer-s-bluerock-therapeutics-expands-to-europe-with-new-berlin-site 2022-06-09T01:22:41+00:00 weekly 0.7 https://trial.medpath.com/news/liquid-biopsy-technology-fda-s-latest-guidance-supports-cooley 2022-06-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/liquid-biopsy-technology-fda-s-latest-guidance-supports-cooley 2022-06-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/dbv-technologies-announces-positive-topline-results-from-phase-3-epitope-trial-of-viaskin-peanut-in-peanut-allergic-toddlers 2022-06-07T20:36:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dbv-technologies-announces-positive-topline-results-from-phase-3-epitope-trial-of-viaskin-peanut-in-peanut-allergic-toddlers 2022-06-07T20:36:06+00:00 weekly 0.7 https://trial.medpath.com/news/dostarlimab-achieves-100-complete-response-rate-in-rectal-cancer-trial-with-mismatch-repair-deficiency 2022-06-06T18:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dostarlimab-achieves-100-complete-response-rate-in-rectal-cancer-trial-with-mismatch-repair-deficiency 2022-06-06T18:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/eli-lilly-s-tirzepatide-shows-unprecedented-22-5-weight-loss-in-phase-3-obesity-trial 2022-06-06T10:03:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eli-lilly-s-tirzepatide-shows-unprecedented-22-5-weight-loss-in-phase-3-obesity-trial 2022-06-06T10:03:51+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-fifth-neulasta-biosimilar 2022-06-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-fifth-neulasta-biosimilar 2022-06-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/eagle-pharmaceuticals-submits-nda-for-landiolol-ultra-short-acting-beta-blocker-for-critical-care-tachycardia 2022-06-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eagle-pharmaceuticals-submits-nda-for-landiolol-ultra-short-acting-beta-blocker-for-critical-care-tachycardia 2022-06-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/risankizumab-as-induction-therapy-for-crohn-s-disease-results 2022-05-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/risankizumab-as-induction-therapy-for-crohn-s-disease-results 2022-05-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/abbvie-s-risankizumab-and-upadacitinib-show-promise-in-phase-3-ibd-trials-published-in-the-lancet 2022-05-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abbvie-s-risankizumab-and-upadacitinib-show-promise-in-phase-3-ibd-trials-published-in-the-lancet 2022-05-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/i-mab-reports-latest-phase-2-clinical-data-of-its-differentiated-cd73 2022-05-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/i-mab-reports-latest-phase-2-clinical-data-of-its-differentiated-cd73 2022-05-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/phase-ii-study-shows-atacicept-s-potential-in-treating-iga-nephropathy 2022-05-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-ii-study-shows-atacicept-s-potential-in-treating-iga-nephropathy 2022-05-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-ivosidenib-plus-azacitidine-for-certain-patients-with-acute-myeloid-leukemia 2022-05-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-ivosidenib-plus-azacitidine-for-certain-patients-with-acute-myeloid-leukemia 2022-05-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/comparative-evaluation-of-laxaplus-barij-r-and-polyethylene-glycol-in-pediatric-functional-constipation 2022-05-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/comparative-evaluation-of-laxaplus-barij-r-and-polyethylene-glycol-in-pediatric-functional-constipation 2022-05-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/the-fda-approves-epsolay-cream-for-rosacea-treatment-spa-clinic 2022-05-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-fda-approves-epsolay-cream-for-rosacea-treatment-spa-clinic 2022-05-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/efficacy-and-safety-of-elian-granules-in-treating-chronic-atrophic-gastritis 2022-05-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/efficacy-and-safety-of-elian-granules-in-treating-chronic-atrophic-gastritis 2022-05-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/real-world-evidence-of-axicabtagene-ciloleucel-for-the-treatment-of 2022-05-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/real-world-evidence-of-axicabtagene-ciloleucel-for-the-treatment-of 2022-05-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/teclistamab-daratumumab-combination-shows-promising-results-in-heavily-pretreated-multiple-myeloma-patients 2022-05-20T18:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/teclistamab-daratumumab-combination-shows-promising-results-in-heavily-pretreated-multiple-myeloma-patients 2022-05-20T18:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/moderna-faces-patent-infringement-lawsuit-over-lipid-nanoparticle-technology-in-covid-19-vaccine 2022-05-19T09:35:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/moderna-faces-patent-infringement-lawsuit-over-lipid-nanoparticle-technology-in-covid-19-vaccine 2022-05-19T09:35:35+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-nct04857372-uchicago-medicine 2022-05-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-trial-nct04857372-uchicago-medicine 2022-05-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/sorrento-s-license-partner-lee-s-pharm-announces-full-enrollment-in-phase-iii-trial-of-socazolimab-for-es-sclc 2022-05-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sorrento-s-license-partner-lee-s-pharm-announces-full-enrollment-in-phase-iii-trial-of-socazolimab-for-es-sclc 2022-05-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ultragenyx-acquires-global-rights-to-aav-gene-therapy 2022-05-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ultragenyx-acquires-global-rights-to-aav-gene-therapy 2022-05-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a-pathological-complete-response-after-nivolumab-plus 2022-05-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-pathological-complete-response-after-nivolumab-plus 2022-05-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cullinan-oncology-and-taiho-pharmaceutical-forge-275m-strategic-collaboration-for-egfr-inhibitor-cln-081-tas6417 2022-05-12T03:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cullinan-oncology-and-taiho-pharmaceutical-forge-275m-strategic-collaboration-for-egfr-inhibitor-cln-081-tas6417 2022-05-12T03:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/single-cell-study-reveals-jun-as-key-regulator-in-cardiovascular-aging 2022-05-08T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/single-cell-study-reveals-jun-as-key-regulator-in-cardiovascular-aging 2022-05-08T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/delaware-jury-awards-bgi-333-8-million-in-dna-sequencing-patent-victory-against-illumina 2022-05-06T19:45:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/delaware-jury-awards-bgi-333-8-million-in-dna-sequencing-patent-victory-against-illumina 2022-05-06T19:45:48+00:00 weekly 0.7 https://trial.medpath.com/news/car-t-cell-therapy-advances-from-manufacturing-innovations-to-solid-tumor-breakthroughs 2022-05-05T17:30:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/car-t-cell-therapy-advances-from-manufacturing-innovations-to-solid-tumor-breakthroughs 2022-05-05T17:30:21+00:00 weekly 0.7 https://trial.medpath.com/news/pharmather-secures-u-s-patent-for-advanced-ketamine-production-technology 2022-05-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pharmather-secures-u-s-patent-for-advanced-ketamine-production-technology 2022-05-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/4sc-resminostat-and-resmain-study-update-4sc-ag 2022-05-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/4sc-resminostat-and-resmain-study-update-4sc-ag 2022-05-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/seastar-medical-receives-fda-breakthrough-device-designation-for-novel-therapy 2022-05-03T08:25:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/seastar-medical-receives-fda-breakthrough-device-designation-for-novel-therapy 2022-05-03T08:25:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-breakthrough-therapy-designation-to-trastuzumab-deruxtecan-for-her2-low-metastatic-breast-cancer 2022-05-01T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-breakthrough-therapy-designation-to-trastuzumab-deruxtecan-for-her2-low-metastatic-breast-cancer 2022-05-01T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/six-monthly-injection-shows-promise-as-alternative-to-daily-blood-pressure-medication-in-global-trial 2022-04-27T13:14:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/six-monthly-injection-shows-promise-as-alternative-to-daily-blood-pressure-medication-in-global-trial 2022-04-27T13:14:54+00:00 weekly 0.7 https://trial.medpath.com/news/dual-targeting-car-t-therapies-show-promise-in-overcoming-b-cell-cancer-treatment-resistance 2022-04-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dual-targeting-car-t-therapies-show-promise-in-overcoming-b-cell-cancer-treatment-resistance 2022-04-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/study-shows-promising-results-for-bioresorbable-polymer-scaffold-in-spinal-cord-injury-patients 2022-04-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-shows-promising-results-for-bioresorbable-polymer-scaffold-in-spinal-cord-injury-patients 2022-04-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/current-clinical-trials-in-traumatic-brain-injury 2022-04-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/current-clinical-trials-in-traumatic-brain-injury 2022-04-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/diet-and-gut-microbiota-shape-development-of-regulatory-t-cells-study-finds 2022-04-19T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/diet-and-gut-microbiota-shape-development-of-regulatory-t-cells-study-finds 2022-04-19T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/canada-abandons-controversial-drug-pricing-reforms-following-court-ruling 2022-04-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/canada-abandons-controversial-drug-pricing-reforms-following-court-ruling 2022-04-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/novel-therapies-transform-multiple-myeloma-treatment-landscape-car-t-bispecifics-lead-innovation-wave 2022-04-15T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novel-therapies-transform-multiple-myeloma-treatment-landscape-car-t-bispecifics-lead-innovation-wave 2022-04-15T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-sotorasib-for-kras-g12c-mutated-metastatic-nsclc 2022-04-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-sotorasib-for-kras-g12c-mutated-metastatic-nsclc 2022-04-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/u-s-fda-extends-review-of-biologics-license-application 2022-04-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/u-s-fda-extends-review-of-biologics-license-application 2022-04-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/new-research-defines-positive-mental-health-literacy-as-key-to-psychological-wellbeing 2022-04-13T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-research-defines-positive-mental-health-literacy-as-key-to-psychological-wellbeing 2022-04-13T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/bo-112-plus-pembrolizumab-shows-promise-in-pd-1-resistant-advanced-melanoma 2022-04-12T20:30:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bo-112-plus-pembrolizumab-shows-promise-in-pd-1-resistant-advanced-melanoma 2022-04-12T20:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/aeglea-biotherapeutics-submits-bla-for-pegzilarginase-as-first-potential-treatment-for-arginase-1-deficiency 2022-04-12T10:52:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aeglea-biotherapeutics-submits-bla-for-pegzilarginase-as-first-potential-treatment-for-arginase-1-deficiency 2022-04-12T10:52:00+00:00 weekly 0.7 https://trial.medpath.com/news/dr-tagawa-on-the-investigation-of-225ac-j591-and-177lu 2022-04-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dr-tagawa-on-the-investigation-of-225ac-j591-and-177lu 2022-04-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/study-finds-drug-treatment-effective-for-crohn-s-disease-strictures 2022-04-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-finds-drug-treatment-effective-for-crohn-s-disease-strictures 2022-04-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/acadia-to-seek-first-ever-fda-approval-in-rett-syndrome 2022-04-07T10:21:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/acadia-to-seek-first-ever-fda-approval-in-rett-syndrome 2022-04-07T10:21:48+00:00 weekly 0.7 https://trial.medpath.com/news/direct-biologics-reveals-successful-outcomes-from-exit-covid-19-phase-ii-clinical-trial 2022-04-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/direct-biologics-reveals-successful-outcomes-from-exit-covid-19-phase-ii-clinical-trial 2022-04-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/first-patient-dosed-in-phase-2b-trial-of-rt234-a-novel-inhaled-therapy-for-pulmonary-arterial-hypertension 2022-04-05T12:06:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-patient-dosed-in-phase-2b-trial-of-rt234-a-novel-inhaled-therapy-for-pulmonary-arterial-hypertension 2022-04-05T12:06:25+00:00 weekly 0.7 https://trial.medpath.com/news/sequana-medical-completes-alfapump-implantations-in-poseidon-study 2022-04-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sequana-medical-completes-alfapump-implantations-in-poseidon-study 2022-04-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/pacritinib-paves-a-unique-lane-of-treatment-for-select 2022-04-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pacritinib-paves-a-unique-lane-of-treatment-for-select 2022-04-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/china-clears-cansinobio-covid-19-vaccine-for-clinical-trials-national-globalnews-ca 2022-04-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/china-clears-cansinobio-covid-19-vaccine-for-clinical-trials-national-globalnews-ca 2022-04-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/junshi-biosciences-announces-fda-approval-of-investigational-new-drug-application-for-anti-cd112r-monoclonal-antibody-for-treatment-of-advanced-solid-tumors-financial-post 2022-04-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/junshi-biosciences-announces-fda-approval-of-investigational-new-drug-application-for-anti-cd112r-monoclonal-antibody-for-treatment-of-advanced-solid-tumors-financial-post 2022-04-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/clarity-pharmaceuticals-launches-cobra-trial-testing-novel-cu-64-sar-bispsma-imaging-agent-for-biochemically-recurrent-prostate-cancer 2022-04-01T16:17:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clarity-pharmaceuticals-launches-cobra-trial-testing-novel-cu-64-sar-bispsma-imaging-agent-for-biochemically-recurrent-prostate-cancer 2022-04-01T16:17:02+00:00 weekly 0.7 https://trial.medpath.com/news/phase-1-dose-expansion-trial-of-brentuximab-vedotin-and-lenalidomide-in-relapsed-or-refractory-diffuse-large-b-cell-lymphoma 2022-03-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-1-dose-expansion-trial-of-brentuximab-vedotin-and-lenalidomide-in-relapsed-or-refractory-diffuse-large-b-cell-lymphoma 2022-03-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/aion-labs-launches-ai-initiative-to-revolutionize-antibody-drug-development 2022-03-27T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aion-labs-launches-ai-initiative-to-revolutionize-antibody-drug-development 2022-03-27T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/hhs-terminates-500-million-in-federal-mrna-vaccine-research-funding-under-kennedy-leadership 2022-03-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hhs-terminates-500-million-in-federal-mrna-vaccine-research-funding-under-kennedy-leadership 2022-03-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/us-food-and-drug-administration-revises-emergency-use 2022-03-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/us-food-and-drug-administration-revises-emergency-use 2022-03-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/pipeline-watch-13-approvals-and-five-topline-phase-iii-readouts 2022-03-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pipeline-watch-13-approvals-and-five-topline-phase-iii-readouts 2022-03-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/biopharma-companies-see-massive-potential-in-connected-health-despite-low-adoption-rates 2022-03-22T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biopharma-companies-see-massive-potential-in-connected-health-despite-low-adoption-rates 2022-03-22T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/vr-and-ar-technologies-transform-pharmaceutical-manufacturing-training-promising-50-faster-onboarding 2022-03-21T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vr-and-ar-technologies-transform-pharmaceutical-manufacturing-training-promising-50-faster-onboarding 2022-03-21T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/orphan-drug-market-set-to-reach-350-billion-by-2028-as-rare-disease-treatments-expand 2022-03-18T14:31:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/orphan-drug-market-set-to-reach-350-billion-by-2028-as-rare-disease-treatments-expand 2022-03-18T14:31:10+00:00 weekly 0.7 https://trial.medpath.com/news/feasibility-and-acceptability-of-a-mobile-application-to-monitor-opioid-use-post-cesarean-section 2022-03-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/feasibility-and-acceptability-of-a-mobile-application-to-monitor-opioid-use-post-cesarean-section 2022-03-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/advancements-in-immune-checkpoint-inhibitor-based-systemic-therapy-for-hepatocellular-carcinoma 2022-03-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/advancements-in-immune-checkpoint-inhibitor-based-systemic-therapy-for-hepatocellular-carcinoma 2022-03-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/eskayef-pharmaceuticals-becomes-third-bangladeshi-company-to-receive-us-fda-approval-for-manufacturing-facility 2022-03-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eskayef-pharmaceuticals-becomes-third-bangladeshi-company-to-receive-us-fda-approval-for-manufacturing-facility 2022-03-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/pfizer-begins-phase-2-and-3-trial-of-covid-19-antiviral-paxlovid-in-children-ages-6-to-17-cnn 2022-03-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pfizer-begins-phase-2-and-3-trial-of-covid-19-antiviral-paxlovid-in-children-ages-6-to-17-cnn 2022-03-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/promising-brain-cancer-vaccine-survaxm-enters-phase-2b-trial-for-newly-diagnosed-glioblastoma 2022-03-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/promising-brain-cancer-vaccine-survaxm-enters-phase-2b-trial-for-newly-diagnosed-glioblastoma 2022-03-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-carvykti-car-t-cell-therapy-for-multiple 2022-03-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-carvykti-car-t-cell-therapy-for-multiple 2022-03-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/comparative-efficacy-of-treatment-regimens-for-transplant-ineligible-patients-with-newly-diagnosed-multiple-myeloma 2022-03-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/comparative-efficacy-of-treatment-regimens-for-transplant-ineligible-patients-with-newly-diagnosed-multiple-myeloma 2022-03-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/i-mab-receives-fda-orphan-drug-designation-for-its-novel-claudin-18-2-x 2022-03-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/i-mab-receives-fda-orphan-drug-designation-for-its-novel-claudin-18-2-x 2022-03-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/exploring-the-role-of-immunotherapy-after-progression-in-renal-cell-carcinoma 2022-03-02T14:00:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/exploring-the-role-of-immunotherapy-after-progression-in-renal-cell-carcinoma 2022-03-02T14:00:18+00:00 weekly 0.7 https://trial.medpath.com/news/psychedelic-medicine-gains-mainstream-acceptance-as-mental-health-crisis-drives-research-innovation 2022-03-01T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/psychedelic-medicine-gains-mainstream-acceptance-as-mental-health-crisis-drives-research-innovation 2022-03-01T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trials-missing-in-regulatory-documents-for-extended-release-methylphenidate-applications 2022-03-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-trials-missing-in-regulatory-documents-for-extended-release-methylphenidate-applications 2022-03-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/combination-therapy-shows-promise-for-advanced-hepatocellular-carcinoma 2022-03-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/combination-therapy-shows-promise-for-advanced-hepatocellular-carcinoma 2022-03-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/primary-care-sites-emerge-as-vital-hub-for-clinical-research-innovation-experts-highlight 2022-02-28T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/primary-care-sites-emerge-as-vital-hub-for-clinical-research-innovation-experts-highlight 2022-02-28T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/first-wholly-ai-developed-drug-enters-phase-1-trials 2022-02-25T04:45:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-wholly-ai-developed-drug-enters-phase-1-trials 2022-02-25T04:45:46+00:00 weekly 0.7 https://trial.medpath.com/news/new-sanofi-and-gsk-vaccine-demonstrates-strong-protection-against-severe-covid-19-in-clinical-trials-cnn 2022-02-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-sanofi-and-gsk-vaccine-demonstrates-strong-protection-against-severe-covid-19-in-clinical-trials-cnn 2022-02-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/real-world-evidence-shows-immune-checkpoint-inhibitors-benefit-nsclc-patients-with-poor-performance-status 2022-02-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/real-world-evidence-shows-immune-checkpoint-inhibitors-benefit-nsclc-patients-with-poor-performance-status 2022-02-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/agios-announces-fda-approval-of-pyrukynd-r-mitapivat-as-globenewswire 2022-02-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/agios-announces-fda-approval-of-pyrukynd-r-mitapivat-as-globenewswire 2022-02-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-highlights-positive-effects-of-medical-cannabis-on-ptsd 2022-02-16T15:23:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-trial-highlights-positive-effects-of-medical-cannabis-on-ptsd 2022-02-16T15:23:20+00:00 weekly 0.7 https://trial.medpath.com/news/poly-adp-ribose-polymerase-parp-inhibitors-for-the 2022-02-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/poly-adp-ribose-polymerase-parp-inhibitors-for-the 2022-02-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/challenges-and-recommendations-in-glioblastoma-clinical-trials 2022-02-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/challenges-and-recommendations-in-glioblastoma-clinical-trials 2022-02-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/pipeline-rise-therapeutics 2022-02-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pipeline-rise-therapeutics 2022-02-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-plan-to-fast-track-pfizer-vaccine-for-kids-under-5-fails-to-deliver-leaving-parents-waiting-until-april 2022-02-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-plan-to-fast-track-pfizer-vaccine-for-kids-under-5-fails-to-deliver-leaving-parents-waiting-until-april 2022-02-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/chromadex-strengthens-patent-portfolio-with-two-new-continuation-patents-for-nicotinamide-riboside-manufacturing 2022-02-09T11:36:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/chromadex-strengthens-patent-portfolio-with-two-new-continuation-patents-for-nicotinamide-riboside-manufacturing 2022-02-09T11:36:07+00:00 weekly 0.7 https://trial.medpath.com/news/combination-therapy-for-pancreatic-cancer-anti-pd-l-1-based-strategy 2022-02-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/combination-therapy-for-pancreatic-cancer-anti-pd-l-1-based-strategy 2022-02-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cytokinetics-announces-fda-acceptance-of-new-drug-globenewswire 2022-02-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cytokinetics-announces-fda-acceptance-of-new-drug-globenewswire 2022-02-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/moderna-s-covid-19-vaccine-spikevax-receives-full-fda-approval-marking-company-s-first-licensed-product 2022-01-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/moderna-s-covid-19-vaccine-spikevax-receives-full-fda-approval-marking-company-s-first-licensed-product 2022-01-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/calliditas-reports-positive-phase-iii-results-for-nefecon-plans-full-fda-approval-filing-in-2023 2022-01-28T07:31:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/calliditas-reports-positive-phase-iii-results-for-nefecon-plans-full-fda-approval-filing-in-2023 2022-01-28T07:31:00+00:00 weekly 0.7 https://trial.medpath.com/news/early-research-suggests-cancer-drug-could-help-flush-hiv-from-its-hiding-spots 2022-01-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/early-research-suggests-cancer-drug-could-help-flush-hiv-from-its-hiding-spots 2022-01-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/transitioning-ongoing-studies-to-the-eu-clinical-trial-regulation 2022-01-25T15:09:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/transitioning-ongoing-studies-to-the-eu-clinical-trial-regulation 2022-01-25T15:09:00+00:00 weekly 0.7 https://trial.medpath.com/news/can-cbd-treat-covid-19-clinical-trials-still-needed-researchers-warn-national-globalnews-ca 2022-01-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/can-cbd-treat-covid-19-clinical-trials-still-needed-researchers-warn-national-globalnews-ca 2022-01-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/johnson-johnson-medtech-receives-ce-mark-approval-for-advanced-dual-energy-thermocool-smarttouch-sf-catheter 2022-01-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/johnson-johnson-medtech-receives-ce-mark-approval-for-advanced-dual-energy-thermocool-smarttouch-sf-catheter 2022-01-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/adimab-announces-2021-clinical-pipeline-update-with-12-new-partner-programs 2022-01-19T05:13:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/adimab-announces-2021-clinical-pipeline-update-with-12-new-partner-programs 2022-01-19T05:13:42+00:00 weekly 0.7 https://trial.medpath.com/news/prophylactic-tranexamic-acid-in-hematologic-malignancy-patients-a-randomized-clinical-trial 2022-01-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/prophylactic-tranexamic-acid-in-hematologic-malignancy-patients-a-randomized-clinical-trial 2022-01-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/edap-announces-positive-pre-clinical-results-for-hifu-ablation-in-pancreatic-cancer-treatment 2022-01-13T13:06:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/edap-announces-positive-pre-clinical-results-for-hifu-ablation-in-pancreatic-cancer-treatment 2022-01-13T13:06:04+00:00 weekly 0.7 https://trial.medpath.com/news/personalized-prediction-model-for-alzheimer-s-disease-progression-and-donepezil-treatment-effects 2022-01-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/personalized-prediction-model-for-alzheimer-s-disease-progression-and-donepezil-treatment-effects 2022-01-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ideaya-biosciences-announces-corporate-and-portfolio-updates-at-j-p-morgan-healthcare-conference 2022-01-10T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ideaya-biosciences-announces-corporate-and-portfolio-updates-at-j-p-morgan-healthcare-conference 2022-01-10T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/maze-therapeutics-announces-190-million-financing 2022-01-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/maze-therapeutics-announces-190-million-financing 2022-01-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ascendis-pharma-a-s-updates-on-vision-3x3-strategy-and-2022-milestones 2022-01-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ascendis-pharma-a-s-updates-on-vision-3x3-strategy-and-2022-milestones 2022-01-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/icecure-medical-ceo-highlights-2021-achievements-and-2022-objectives 2022-01-05T08:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/icecure-medical-ceo-highlights-2021-achievements-and-2022-objectives 2022-01-05T08:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/nice-rejects-astrazeneca-s-lynparza-for-prostate-cancer-despite-scottish-approval 2022-01-04T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nice-rejects-astrazeneca-s-lynparza-for-prostate-cancer-despite-scottish-approval 2022-01-04T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/research-ethics-board-approves-amendment-to-canadian-covid-19-treatment-trial-to-include-lsalt-peptide 2022-01-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/research-ethics-board-approves-amendment-to-canadian-covid-19-treatment-trial-to-include-lsalt-peptide 2022-01-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/safety-and-efficacy-of-aadc-gene-therapy-for-moderately-advanced-parkinson-disease-three-year-outcomes 2022-01-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/safety-and-efficacy-of-aadc-gene-therapy-for-moderately-advanced-parkinson-disease-three-year-outcomes 2022-01-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/real-world-faricimab-namd-outcomes 2022-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/real-world-faricimab-namd-outcomes 2022-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fruquintinib-granted-us-fda-fast-track-designation-for-metastatic-colorectal-cancer-treatment 2022-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fruquintinib-granted-us-fda-fast-track-designation-for-metastatic-colorectal-cancer-treatment 2022-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/hutchmed-announces-savolitinib-snda-accepted-in-china-for-nsclc-treatment 2022-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hutchmed-announces-savolitinib-snda-accepted-in-china-for-nsclc-treatment 2022-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/hutchmed-to-present-key-clinical-data-for-multiple-cancer-therapies-at-asco-2025 2022-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hutchmed-to-present-key-clinical-data-for-multiple-cancer-therapies-at-asco-2025 2022-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/limmatech-awarded-fda-fast-track-designation-for-vaccine-candidate 2022-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/limmatech-awarded-fda-fast-track-designation-for-vaccine-candidate 2022-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-verrica-s-ycanth-first-treatment-for-molluscum-contagiosum 2022-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-verrica-s-ycanth-first-treatment-for-molluscum-contagiosum 2022-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/teprotumumab-tepezza-approved-for-thyroid-eye-disease-treatment 2022-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/teprotumumab-tepezza-approved-for-thyroid-eye-disease-treatment 2022-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/treatment-of-multiple-sclerosis-related-trigeminal-neuralgia-with 2022-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/treatment-of-multiple-sclerosis-related-trigeminal-neuralgia-with 2022-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/events-circulars-forms 2022-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/events-circulars-forms 2022-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a-multi-center-open-label-single-arm-trial-to-evaluate-the-efficacy 2022-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-multi-center-open-label-single-arm-trial-to-evaluate-the-efficacy 2022-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/decentralized-clinical-trials-show-promise-in-expanding-healthcare-access-and-diversity 2021-12-31T08:05:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/decentralized-clinical-trials-show-promise-in-expanding-healthcare-access-and-diversity 2021-12-31T08:05:00+00:00 weekly 0.7 https://trial.medpath.com/news/mercury-biomed-awarded-1-5m-national-institutes-of-health-grant-ap-news 2021-12-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mercury-biomed-awarded-1-5m-national-institutes-of-health-grant-ap-news 2021-12-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/car-t-cell-therapy-shows-promise-in-treating-b-cell-lymphoma 2021-12-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/car-t-cell-therapy-shows-promise-in-treating-b-cell-lymphoma 2021-12-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/real-world-assessment-of-patient-care-and-practice-efficiency-with-subcutaneous-rituximab 2021-12-22T15:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/real-world-assessment-of-patient-care-and-practice-efficiency-with-subcutaneous-rituximab 2021-12-22T15:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/insilico-medicine-initiates-first-in-human-study-of-ism001-055 2021-12-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/insilico-medicine-initiates-first-in-human-study-of-ism001-055 2021-12-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/eu-approves-apellis-and-sobi-s-aspaveli-for-pnh-with-restricted-label 2021-12-14T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eu-approves-apellis-and-sobi-s-aspaveli-for-pnh-with-restricted-label 2021-12-14T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/advances-in-parp-inhibitor-combinations-show-promise-for-ovarian-cancer-treatment 2021-12-14T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/advances-in-parp-inhibitor-combinations-show-promise-for-ovarian-cancer-treatment 2021-12-14T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/polatuzumab-vedotin-shows-superior-efficacy-in-first-line-dlbcl-treatment-and-confirms-long-term-benefits-in-relapsed-disease 2021-12-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/polatuzumab-vedotin-shows-superior-efficacy-in-first-line-dlbcl-treatment-and-confirms-long-term-benefits-in-relapsed-disease 2021-12-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/sentinel-lymph-node-biopsy-after-neoadjuvant-therapy-shows-promise-in-node-positive-breast-cancer-patients 2021-12-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sentinel-lymph-node-biopsy-after-neoadjuvant-therapy-shows-promise-in-node-positive-breast-cancer-patients 2021-12-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/als-drug-development-gains-momentum-with-new-research-approaches-and-industry-investment 2021-12-12T16:01:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/als-drug-development-gains-momentum-with-new-research-approaches-and-industry-investment 2021-12-12T16:01:00+00:00 weekly 0.7 https://trial.medpath.com/news/samuraciclib-plus-fulvestrant-shows-promising-results-in-heavily-pretreated-hr-breast-cancer 2021-12-10T18:22:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/samuraciclib-plus-fulvestrant-shows-promising-results-in-heavily-pretreated-hr-breast-cancer 2021-12-10T18:22:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-first-eye-drops-for-presbyopia-treatment-offering-alternative-to-reading-glasses 2021-12-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-first-eye-drops-for-presbyopia-treatment-offering-alternative-to-reading-glasses 2021-12-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/zanidatamab-plus-chemotherapy-shows-promising-results-in-heavily-pretreated-her2-positive-breast-cancer 2021-12-09T17:45:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/zanidatamab-plus-chemotherapy-shows-promising-results-in-heavily-pretreated-her2-positive-breast-cancer 2021-12-09T17:45:15+00:00 weekly 0.7 https://trial.medpath.com/news/anti-covid-19-drug-authorized-in-us-for-those-uneligible-for-vaccination 2021-12-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/anti-covid-19-drug-authorized-in-us-for-those-uneligible-for-vaccination 2021-12-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/gh-research-announces-successful-outcome-of-phase-2-clinical-trial-for-gh001-in-treatment-resistant-depression 2021-12-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gh-research-announces-successful-outcome-of-phase-2-clinical-trial-for-gh001-in-treatment-resistant-depression 2021-12-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-insightec-s-exablate-neuro-for-advanced-parkinson-s-disease-treatment 2021-12-03T13:20:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-insightec-s-exablate-neuro-for-advanced-parkinson-s-disease-treatment 2021-12-03T13:20:55+00:00 weekly 0.7 https://trial.medpath.com/news/minocycline-extended-release-comparison-with-doxycycline-for-the-treatment-of-rosacea-a-randomized-head-to-head-clinical-trial-jcad-the-journal-of-clinical-and-aesthetic-dermatology 2021-12-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/minocycline-extended-release-comparison-with-doxycycline-for-the-treatment-of-rosacea-a-randomized-head-to-head-clinical-trial-jcad-the-journal-of-clinical-and-aesthetic-dermatology 2021-12-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/gene-therapy-for-duchenne-muscular-dystrophy-pmc 2021-11-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gene-therapy-for-duchenne-muscular-dystrophy-pmc 2021-11-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-orphan-drug-designation-to-ct120-dual-targeted-car-t-therapy-for-acute-lymphoblastic-leukemia 2021-11-26T15:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-orphan-drug-designation-to-ct120-dual-targeted-car-t-therapy-for-acute-lymphoblastic-leukemia 2021-11-26T15:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/real-world-evidence-increasingly-influences-fda-drug-approvals-study-finds 2021-11-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/real-world-evidence-increasingly-influences-fda-drug-approvals-study-finds 2021-11-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/study-finds-escitalopram-reduces-adverse-effects-of-psilocybin-without-affecting-positive-mood-effects 2021-11-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-finds-escitalopram-reduces-adverse-effects-of-psilocybin-without-affecting-positive-mood-effects 2021-11-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/global-summit-to-address-breakthrough-therapies-for-mitochondrial-diseases 2021-11-21T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/global-summit-to-address-breakthrough-therapies-for-mitochondrial-diseases 2021-11-21T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/next-generation-kinase-inhibitors-summit-to-address-key-challenges-in-cancer-treatment-development 2021-11-21T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/next-generation-kinase-inhibitors-summit-to-address-key-challenges-in-cancer-treatment-development 2021-11-21T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/discovery-expands-donor-pool-for-stem-cell-transplants-in-cancer-patients 2021-11-19T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/discovery-expands-donor-pool-for-stem-cell-transplants-in-cancer-patients 2021-11-19T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/chop-led-study-shows-novel-gene-therapy-for-hemophilia-a-leads-to-sustained-expression-of-clotting-factor-and-reduced-bleeding-events 2021-11-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/chop-led-study-shows-novel-gene-therapy-for-hemophilia-a-leads-to-sustained-expression-of-clotting-factor-and-reduced-bleeding-events 2021-11-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fasting-mimicking-diet-shows-promise-in-modulating-metabolism-and-enhancing-antitumor-immunity-in-cancer-patients 2021-11-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fasting-mimicking-diet-shows-promise-in-modulating-metabolism-and-enhancing-antitumor-immunity-in-cancer-patients 2021-11-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/singapore-launches-project-golden-years-groundbreaking-qualitative-study-on-dementia-prevention-attitudes 2021-11-16T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/singapore-launches-project-golden-years-groundbreaking-qualitative-study-on-dementia-prevention-attitudes 2021-11-16T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/shorter-course-of-radiation-therapy-proves-safe-and-effective-for-post-surgery-prostate-cancer-patients 2021-11-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/shorter-course-of-radiation-therapy-proves-safe-and-effective-for-post-surgery-prostate-cancer-patients 2021-11-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ema-grants-orphan-drug-designation-to-rafael 2021-11-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ema-grants-orphan-drug-designation-to-rafael 2021-11-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/clarity-pharmaceuticals-completes-dosimetry-phase-of-sar-bispsma-theranostic-trial-for-metastatic-prostate-cancer 2021-11-10T09:06:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clarity-pharmaceuticals-completes-dosimetry-phase-of-sar-bispsma-theranostic-trial-for-metastatic-prostate-cancer 2021-11-10T09:06:00+00:00 weekly 0.7 https://trial.medpath.com/news/arbor-biotechnologies-secures-215m-series-b-to-advance-crispr-gene-editing-platform 2021-11-09T07:47:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/arbor-biotechnologies-secures-215m-series-b-to-advance-crispr-gene-editing-platform 2021-11-09T07:47:07+00:00 weekly 0.7 https://trial.medpath.com/news/scope-biosciences-secures-eur1m-investment-to-advance-crispr-based-diagnostic-platform 2021-11-08T17:20:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/scope-biosciences-secures-eur1m-investment-to-advance-crispr-based-diagnostic-platform 2021-11-08T17:20:00+00:00 weekly 0.7 https://trial.medpath.com/news/hkbu-researchers-engineer-exosome-based-delivery-system-for-alzheimer-s-treatment-using-chinese-medicine-compound 2021-11-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hkbu-researchers-engineer-exosome-based-delivery-system-for-alzheimer-s-treatment-using-chinese-medicine-compound 2021-11-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/deepmind-launches-isomorphic-labs-to-transform-drug-discovery-through-ai-innovation 2021-11-04T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/deepmind-launches-isomorphic-labs-to-transform-drug-discovery-through-ai-innovation 2021-11-04T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/hpv-vaccine-shows-87-reduction-in-cervical-cancer-cases-in-landmark-english-study 2021-11-03T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hpv-vaccine-shows-87-reduction-in-cervical-cancer-cases-in-landmark-english-study 2021-11-03T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/repurposed-antiviral-drugs-for-covid-19-interim-who-solidarity 2021-11-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/repurposed-antiviral-drugs-for-covid-19-interim-who-solidarity 2021-11-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-breakthrough-twice-yearly-hiv-prevention-drug-lenacapavir-with-nearly-100-efficacy 2021-11-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-breakthrough-twice-yearly-hiv-prevention-drug-lenacapavir-with-nearly-100-efficacy 2021-11-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-greenlights-novartis-first-in-class-therapy-for-cml-biospace 2021-11-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-greenlights-novartis-first-in-class-therapy-for-cml-biospace 2021-11-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cambridge-cognition-secures-major-contract-for-schizophrenia-trial 2021-10-26T13:15:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cambridge-cognition-secures-major-contract-for-schizophrenia-trial 2021-10-26T13:15:00+00:00 weekly 0.7 https://trial.medpath.com/news/european-pharmaceutical-strategy-aims-to-strengthen-supply-chains-and-foster-innovation-post-covid 2021-10-25T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/european-pharmaceutical-strategy-aims-to-strengthen-supply-chains-and-foster-innovation-post-covid 2021-10-25T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-roche-s-susvimo-first-refillable-eye-implant-for-wet-amd-treatment 2021-10-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-roche-s-susvimo-first-refillable-eye-implant-for-wet-amd-treatment 2021-10-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/half-dose-glucarpidase-as-efficient-rescue-for-toxic-methotrexate 2021-10-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/half-dose-glucarpidase-as-efficient-rescue-for-toxic-methotrexate 2021-10-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/plus-therapeutics-receives-fda-clearance-for-186rnl-radiotherapy-trial-in-leptomeningeal-metastases 2021-10-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/plus-therapeutics-receives-fda-clearance-for-186rnl-radiotherapy-trial-in-leptomeningeal-metastases 2021-10-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/orphagen-pharmaceuticals-awarded-sbir-phase-ii-grant-to-develop-a-first-in-class-drug-for-adrenocortical-cancer-orphagen-pharmaceuticals 2021-10-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/orphagen-pharmaceuticals-awarded-sbir-phase-ii-grant-to-develop-a-first-in-class-drug-for-adrenocortical-cancer-orphagen-pharmaceuticals 2021-10-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/covid-19-pandemic-catalyzes-major-transformation-in-global-regulatory-processes 2021-10-17T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/covid-19-pandemic-catalyzes-major-transformation-in-global-regulatory-processes 2021-10-17T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/akadeum-life-sciences-secures-17-5m-series-b-to-advance-microbubble-based-cell-separation-technology 2021-10-12T13:48:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/akadeum-life-sciences-secures-17-5m-series-b-to-advance-microbubble-based-cell-separation-technology 2021-10-12T13:48:37+00:00 weekly 0.7 https://trial.medpath.com/news/heparegenix-initiates-first-in-man-phase-1-trial-for-its-lead-mkk4 2021-10-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/heparegenix-initiates-first-in-man-phase-1-trial-for-its-lead-mkk4 2021-10-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/singapore-researchers-launch-clinical-trial-testing-novel-cell-state-conversion-approach-for-triple-negative-breast-cancer 2021-10-07T08:40:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/singapore-researchers-launch-clinical-trial-testing-novel-cell-state-conversion-approach-for-triple-negative-breast-cancer 2021-10-07T08:40:00+00:00 weekly 0.7 https://trial.medpath.com/news/preliminary-data-on-225ac-j591-shows-promise-in-treating-mcrpc 2021-10-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/preliminary-data-on-225ac-j591-shows-promise-in-treating-mcrpc 2021-10-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/landmark-tosca-registry-reveals-new-insights-into-tuberous-sclerosis-complex-management 2021-10-04T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/landmark-tosca-registry-reveals-new-insights-into-tuberous-sclerosis-complex-management 2021-10-04T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-expansion-of-patient-enrolment-in-sequana-medical-s-poseidon-study-for-alfapump-treatment 2021-10-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-expansion-of-patient-enrolment-in-sequana-medical-s-poseidon-study-for-alfapump-treatment 2021-10-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/laboratory-safety-evaluation-of-bedinvetmab-a-canine-anti 2021-10-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/laboratory-safety-evaluation-of-bedinvetmab-a-canine-anti 2021-10-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/acalabrutinib-venetoclax-and-obinutuzumab-as-frontline 2021-10-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/acalabrutinib-venetoclax-and-obinutuzumab-as-frontline 2021-10-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/tempus-receives-first-fda-clearance-for-ai-based-atrial-fibrillation-risk-detection-algorithm 2021-09-27T19:25:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tempus-receives-first-fda-clearance-for-ai-based-atrial-fibrillation-risk-detection-algorithm 2021-09-27T19:25:59+00:00 weekly 0.7 https://trial.medpath.com/news/4th-rna-targeted-drug-discovery-summit-to-showcase-latest-advances-in-small-molecule-therapeutics 2021-09-27T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/4th-rna-targeted-drug-discovery-summit-to-showcase-latest-advances-in-small-molecule-therapeutics 2021-09-27T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/breakthroughs-in-myocardial-infarction-treatment-new-drugs-on-the-horizon 2021-09-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/breakthroughs-in-myocardial-infarction-treatment-new-drugs-on-the-horizon 2021-09-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fore-biotherapeutics-highlights-recent-pipeline-achievements-and-strategic-objectives-for-2025 2021-09-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fore-biotherapeutics-highlights-recent-pipeline-achievements-and-strategic-objectives-for-2025 2021-09-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trials-loyal-for-dogs 2021-09-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-trials-loyal-for-dogs 2021-09-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/small-business-austin-daily-herald-austin-daily-herald 2021-09-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/small-business-austin-daily-herald-austin-daily-herald 2021-09-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/helping-dogs-live-longer-healthier-lives-loyal 2021-09-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/helping-dogs-live-longer-healthier-lives-loyal 2021-09-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/pierre-fabre-advances-two-phase-ii-trials-of-encorafenib-in-chinese-patients-with-braf-v600e-mutations 2021-09-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pierre-fabre-advances-two-phase-ii-trials-of-encorafenib-in-chinese-patients-with-braf-v600e-mutations 2021-09-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approved-gout-medicine-could-also-battle-covid-19 2021-09-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approved-gout-medicine-could-also-battle-covid-19 2021-09-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/lung-cancer-patients-in-england-to-receive-breakthrough-drug-sotorasib-on-nhs 2021-09-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lung-cancer-patients-in-england-to-receive-breakthrough-drug-sotorasib-on-nhs 2021-09-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/nhs-pioneers-early-access-to-amgen-s-breakthrough-kras-lung-cancer-drug-lumykras 2021-09-09T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nhs-pioneers-early-access-to-amgen-s-breakthrough-kras-lung-cancer-drug-lumykras 2021-09-09T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/meta-analysis-reveals-significant-efficacy-reporting-bias-in-car-t-cell-therapy-clinical-trials 2021-09-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/meta-analysis-reveals-significant-efficacy-reporting-bias-in-car-t-cell-therapy-clinical-trials 2021-09-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/acupuncture-for-combat-post-traumatic-stress-disorder-a-clinical-trial 2021-09-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/acupuncture-for-combat-post-traumatic-stress-disorder-a-clinical-trial 2021-09-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/blockchain-technology-poised-to-transform-healthcare-data-management-and-patient-privacy 2021-09-05T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/blockchain-technology-poised-to-transform-healthcare-data-management-and-patient-privacy 2021-09-05T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a-new-and-validated-randomised-controlled-placebo 2021-09-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-new-and-validated-randomised-controlled-placebo 2021-09-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/monoclonal-antibody-prevents-malaria-in-small-trial-nih-record 2021-09-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/monoclonal-antibody-prevents-malaria-in-small-trial-nih-record 2021-09-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-zanubrutinib-for-waldenstrom-s-macroglobulinemia-treatment 2021-09-01T22:35:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-zanubrutinib-for-waldenstrom-s-macroglobulinemia-treatment 2021-09-01T22:35:51+00:00 weekly 0.7 https://trial.medpath.com/news/nci-and-cdisc-partnership-advances-clinical-trial-data-standardization-through-controlled-terminology 2021-08-31T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nci-and-cdisc-partnership-advances-clinical-trial-data-standardization-through-controlled-terminology 2021-08-31T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/device-therapy-in-chronic-heart-failure-jacc-state-of 2021-08-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/device-therapy-in-chronic-heart-failure-jacc-state-of 2021-08-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/debunking-external-control-arms-myths-new-frontiers-in-clinical-trial-design 2021-08-30T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/debunking-external-control-arms-myths-new-frontiers-in-clinical-trial-design 2021-08-30T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/nci-s-research-on-covid-19-vaccines-and-antibodies 2021-08-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nci-s-research-on-covid-19-vaccines-and-antibodies 2021-08-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/long-non-coding-rnas-emerge-as-key-regulators-of-vascular-endothelium-and-angiogenesis 2021-08-25T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/long-non-coding-rnas-emerge-as-key-regulators-of-vascular-endothelium-and-angiogenesis 2021-08-25T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/patient-centric-trial-design-boosts-recruitment-success-and-launch-probability-by-19 2021-08-25T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/patient-centric-trial-design-boosts-recruitment-success-and-launch-probability-by-19 2021-08-25T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-issues-safety-alert-on-unapproved-robot-assisted-mastectomy-procedures 2021-08-21T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-issues-safety-alert-on-unapproved-robot-assisted-mastectomy-procedures 2021-08-21T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/uk-approves-first-covid-19-monoclonal-antibody-treatment-as-astrazeneca-reports-77-efficacy-in-prevention-trial 2021-08-20T13:43:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/uk-approves-first-covid-19-monoclonal-antibody-treatment-as-astrazeneca-reports-77-efficacy-in-prevention-trial 2021-08-20T13:43:59+00:00 weekly 0.7 https://trial.medpath.com/news/ponatinib-dose-ranging-study-shows-efficacy-in-chronic-phase-cml-patients 2021-08-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ponatinib-dose-ranging-study-shows-efficacy-in-chronic-phase-cml-patients 2021-08-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/dealing-with-breast-cancer-means-also-keeping-in-mind-heart-health 2021-08-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dealing-with-breast-cancer-means-also-keeping-in-mind-heart-health 2021-08-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ucb-announces-u-s-fda-approvals-for-bimzelx-r-bimekizumab-bkzx-for-the-treatment-of-psoriatic-arthritis-non-radiographic-axial-spondyloarthritis-and-ankylosing-spondylitis 2021-08-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ucb-announces-u-s-fda-approvals-for-bimzelx-r-bimekizumab-bkzx-for-the-treatment-of-psoriatic-arthritis-non-radiographic-axial-spondyloarthritis-and-ankylosing-spondylitis 2021-08-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/seagen-secures-2-6b-deal-with-remegen-for-novel-her2-targeting-cancer-drug 2021-08-09T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/seagen-secures-2-6b-deal-with-remegen-for-novel-her2-targeting-cancer-drug 2021-08-09T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/amazon-invests-14-7-million-in-proteome-analysis-company-nautilus-biotechnology 2021-08-05T18:22:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/amazon-invests-14-7-million-in-proteome-analysis-company-nautilus-biotechnology 2021-08-05T18:22:08+00:00 weekly 0.7 https://trial.medpath.com/news/new-drug-combo-shows-early-potential-for-treating 2021-08-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-drug-combo-shows-early-potential-for-treating 2021-08-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/watchdog-to-review-fda-s-approval-process-for-biogen-s-alzheimer-s-drug 2021-08-04T17:21:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/watchdog-to-review-fda-s-approval-process-for-biogen-s-alzheimer-s-drug 2021-08-04T17:21:38+00:00 weekly 0.7 https://trial.medpath.com/news/luye-pharma-s-next-generation-vmat2-inhibitor-ly03015-to-begin-clinical-trials-in-the-u-s 2021-08-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/luye-pharma-s-next-generation-vmat2-inhibitor-ly03015-to-begin-clinical-trials-in-the-u-s 2021-08-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-first-ever-breakthrough-device-status-to-digital-therapeutic-for-heart-failure-management 2021-08-01T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-first-ever-breakthrough-device-status-to-digital-therapeutic-for-heart-failure-management 2021-08-01T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ascentage-pharma-announces-milestone-payment-from-unity-biotechnology-for-senolytic-drug-candidate-ubx1325 2021-07-28T23:26:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ascentage-pharma-announces-milestone-payment-from-unity-biotechnology-for-senolytic-drug-candidate-ubx1325 2021-07-28T23:26:04+00:00 weekly 0.7 https://trial.medpath.com/news/minimal-residual-disease-in-myeloma 2021-07-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/minimal-residual-disease-in-myeloma 2021-07-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/abbvie-and-calico-announce-second-extension-of-collaboration-focused-on-aging-and-age-related-diseases 2021-07-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abbvie-and-calico-announce-second-extension-of-collaboration-focused-on-aging-and-age-related-diseases 2021-07-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-shingrix-for-shingles-prevention-in-immunocompromised-adults 2021-07-26T14:25:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-shingrix-for-shingles-prevention-in-immunocompromised-adults 2021-07-26T14:25:34+00:00 weekly 0.7 https://trial.medpath.com/news/byheart-secures-90m-series-b-financing-and-achieves-all-of-its-clinical-trial-endpoints 2021-07-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/byheart-secures-90m-series-b-financing-and-achieves-all-of-its-clinical-trial-endpoints 2021-07-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/patient-centric-approach-could-transform-unsustainable-oncology-r-d-landscape 2021-07-25T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/patient-centric-approach-could-transform-unsustainable-oncology-r-d-landscape 2021-07-25T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/seres-therapeutics-microbiome-drug-fails-phase-2-ulcerative-colitis-trial-casting-shadow-over-emerging-field 2021-07-22T11:50:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/seres-therapeutics-microbiome-drug-fails-phase-2-ulcerative-colitis-trial-casting-shadow-over-emerging-field 2021-07-22T11:50:00+00:00 weekly 0.7 https://trial.medpath.com/news/attention-sponsors-be-prepared-to-publish-your-interim-clinical-study-results 2021-07-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/attention-sponsors-be-prepared-to-publish-your-interim-clinical-study-results 2021-07-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/psilera-partners-with-worldwide-for-accelerated-clinical-development-of-dmt-patch 2021-07-14T09:00:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/psilera-partners-with-worldwide-for-accelerated-clinical-development-of-dmt-patch 2021-07-14T09:00:34+00:00 weekly 0.7 https://trial.medpath.com/news/fda-lifts-partial-clinical-hold-on-trial-examining-cdk8-cdk19-inhibitor-rvu120-in-aml-mds 2021-07-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-lifts-partial-clinical-hold-on-trial-examining-cdk8-cdk19-inhibitor-rvu120-in-aml-mds 2021-07-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-in-long-covid-detection-blood-test-could-be-available-within-6-12-months 2021-07-11T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/breakthrough-in-long-covid-detection-blood-test-could-be-available-within-6-12-months 2021-07-11T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/china-launches-patent-linkage-system-to-resolve-drug-patent-disputes-before-market-entry 2021-07-07T05:36:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/china-launches-patent-linkage-system-to-resolve-drug-patent-disputes-before-market-entry 2021-07-07T05:36:05+00:00 weekly 0.7 https://trial.medpath.com/news/adjuvant-cdk4-6-inhibitors-combined-with-endocrine 2021-07-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/adjuvant-cdk4-6-inhibitors-combined-with-endocrine 2021-07-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/novel-nlrp3-inflammasome-inhibitors-show-promise-for-treating-multiple-inflammatory-diseases 2021-07-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novel-nlrp3-inflammasome-inhibitors-show-promise-for-treating-multiple-inflammatory-diseases 2021-07-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/iterum-stock-nosedives-as-fda-flags-deficiencies-in-sulopenem-application 2021-07-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/iterum-stock-nosedives-as-fda-flags-deficiencies-in-sulopenem-application 2021-07-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/safety-and-pharmacokinetics-of-casimersen-in-duchenne-muscular-dystrophy-patients 2021-06-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/safety-and-pharmacokinetics-of-casimersen-in-duchenne-muscular-dystrophy-patients 2021-06-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-adds-heart-inflammation-warning-to-moderna-and-pfizer-covid-19-vaccine-fact-sheets 2021-06-26T02:05:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-adds-heart-inflammation-warning-to-moderna-and-pfizer-covid-19-vaccine-fact-sheets 2021-06-26T02:05:08+00:00 weekly 0.7 https://trial.medpath.com/news/rapts-rpt193-in-atopic-dermatitis-drops-by-13-points 2021-06-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rapts-rpt193-in-atopic-dermatitis-drops-by-13-points 2021-06-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/advances-in-car-t-cell-therapy-for-non-hodgkin-lymphoma 2021-06-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/advances-in-car-t-cell-therapy-for-non-hodgkin-lymphoma 2021-06-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/philips-launches-define-gps-trial-to-evaluate-ifr-guided-pci-for-superior-outcomes 2021-06-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/philips-launches-define-gps-trial-to-evaluate-ifr-guided-pci-for-superior-outcomes 2021-06-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/agios-submits-new-drug-application-to-fda-for-mitapivat-for-treatment-of-adults-with-pyruvate-kinase-deficiency 2021-06-21T11:06:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/agios-submits-new-drug-application-to-fda-for-mitapivat-for-treatment-of-adults-with-pyruvate-kinase-deficiency 2021-06-21T11:06:08+00:00 weekly 0.7 https://trial.medpath.com/news/ai-and-automation-set-to-transform-pharmaceutical-r-d-industry-faces-cultural-and-technical-hurdles 2021-06-15T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ai-and-automation-set-to-transform-pharmaceutical-r-d-industry-faces-cultural-and-technical-hurdles 2021-06-15T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-breakthrough-therapy-designation-to-rusfertide-for-polycythemia-vera 2021-06-12T14:42:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-breakthrough-therapy-designation-to-rusfertide-for-polycythemia-vera 2021-06-12T14:42:50+00:00 weekly 0.7 https://trial.medpath.com/news/3-experts-resign-from-fda-panel-over-alzheimer-s-drug-approval 2021-06-11T14:06:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/3-experts-resign-from-fda-panel-over-alzheimer-s-drug-approval 2021-06-11T14:06:40+00:00 weekly 0.7 https://trial.medpath.com/news/phase-i-iia-clinical-trial-of-rh5-1-as01b-vaccine-for-blood-stage-malaria-shows-promising-safety-and-immunogenicity 2021-06-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-i-iia-clinical-trial-of-rh5-1-as01b-vaccine-for-blood-stage-malaria-shows-promising-safety-and-immunogenicity 2021-06-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/laparoscopic-radical-hysterectomy-vs-open-surgery-for-early-stage-cervical-cancer 2021-06-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/laparoscopic-radical-hysterectomy-vs-open-surgery-for-early-stage-cervical-cancer 2021-06-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-aduhelm-first-disease-modifying-alzheimer-s-treatment-in-nearly-two-decades 2021-06-07T15:06:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-aduhelm-first-disease-modifying-alzheimer-s-treatment-in-nearly-two-decades 2021-06-07T15:06:27+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approved-and-emerging-biomarkers-transform-immune-checkpoint-inhibitor-patient-selection 2021-06-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approved-and-emerging-biomarkers-transform-immune-checkpoint-inhibitor-patient-selection 2021-06-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/newly-approved-drug-sotorasib-shows-promise-in-treating-lung-cancer-with-kras-mutation 2021-06-04T18:00:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/newly-approved-drug-sotorasib-shows-promise-in-treating-lung-cancer-with-kras-mutation 2021-06-04T18:00:05+00:00 weekly 0.7 https://trial.medpath.com/news/prognostic-value-of-measurable-residual-disease-monitoring-by-next 2021-06-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/prognostic-value-of-measurable-residual-disease-monitoring-by-next 2021-06-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/first-in-human-study-of-pf-06647020-cofetuzumab-in-patients-with-advanced-solid-tumors 2021-06-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-in-human-study-of-pf-06647020-cofetuzumab-in-patients-with-advanced-solid-tumors 2021-06-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/melanocortin-antagonists-emerge-as-promising-treatment-for-cancer-cachexia 2021-06-02T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/melanocortin-antagonists-emerge-as-promising-treatment-for-cancer-cachexia 2021-06-02T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/hybrytetm-a-promising-skin-directed-therapy-for-cutaneous-t-cell-lymphoma 2021-06-02T14:45:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hybrytetm-a-promising-skin-directed-therapy-for-cutaneous-t-cell-lymphoma 2021-06-02T14:45:55+00:00 weekly 0.7 https://trial.medpath.com/news/iterum-therapeutics-stock-shoots-higher-as-sulopenem-application-review-on-track 2021-05-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/iterum-therapeutics-stock-shoots-higher-as-sulopenem-application-review-on-track 2021-05-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/j-j-s-new-cancer-drug-leads-a-growing-pipeline-of-dual-targeting 2021-05-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/j-j-s-new-cancer-drug-leads-a-growing-pipeline-of-dual-targeting 2021-05-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/lorlatinib-shows-promising-efficacy-in-alk-rearranged-nsclc-with-21-8-month-median-pfs 2021-05-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lorlatinib-shows-promising-efficacy-in-alk-rearranged-nsclc-with-21-8-month-median-pfs 2021-05-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/first-time-drug-launches-mckinsey-data-shows-67-of-products-miss-sales-targets-despite-growing-market-share 2021-05-17T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-time-drug-launches-mckinsey-data-shows-67-of-products-miss-sales-targets-despite-growing-market-share 2021-05-17T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/alume-biosciences-granted-fda-fast-track-designation-of 2021-05-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alume-biosciences-granted-fda-fast-track-designation-of 2021-05-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/healthware-group-unveils-strategic-digital-health-roadmap-for-healthcare-industry-evolution 2021-05-03T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/healthware-group-unveils-strategic-digital-health-roadmap-for-healthcare-industry-evolution 2021-05-03T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/atricure-afib-treatment-device-wins-fda-approval-massdevice 2021-04-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/atricure-afib-treatment-device-wins-fda-approval-massdevice 2021-04-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/iza-bren-adc-achieves-100-response-rate-in-egfr-mutated-nsclc-when-combined-with-osimertinib 2021-04-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/iza-bren-adc-achieves-100-response-rate-in-egfr-mutated-nsclc-when-combined-with-osimertinib 2021-04-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-ventana-mmr-rxdx-panel-as-companion-diagnostic-for-dostarlimab-in-endometrial-cancer 2021-04-22T18:18:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-ventana-mmr-rxdx-panel-as-companion-diagnostic-for-dostarlimab-in-endometrial-cancer 2021-04-22T18:18:25+00:00 weekly 0.7 https://trial.medpath.com/news/rock2-inhibition-with-belumosudil-kd025-shows-promise-in-treating-chronic-graft-versus-host-disease 2021-04-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rock2-inhibition-with-belumosudil-kd025-shows-promise-in-treating-chronic-graft-versus-host-disease 2021-04-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-orphan-drug-status-to-novel-irak4-inhibitor-for-aml-and-mds-treatment 2021-04-19T20:20:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-orphan-drug-status-to-novel-irak4-inhibitor-for-aml-and-mds-treatment 2021-04-19T20:20:00+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-effectiveness-of-lyme-vaccine-a-matched-case-control 2021-04-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-effectiveness-of-lyme-vaccine-a-matched-case-control 2021-04-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-revokes-eua-for-monoclonal-antibody-therapy 2021-04-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-revokes-eua-for-monoclonal-antibody-therapy 2021-04-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/post-pandemic-launch-excellence-three-strategic-pillars-for-pharmaceutical-success 2021-04-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/post-pandemic-launch-excellence-three-strategic-pillars-for-pharmaceutical-success 2021-04-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/spine-biopharma-initiates-phase-3-trial-for-first-in-class-intradiscal-treatment-of-chronic-low-back-pain 2021-04-15T14:43:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/spine-biopharma-initiates-phase-3-trial-for-first-in-class-intradiscal-treatment-of-chronic-low-back-pain 2021-04-15T14:43:14+00:00 weekly 0.7 https://trial.medpath.com/news/car-t-cell-therapy-approved-for-multiple-myeloma 2021-04-14T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/car-t-cell-therapy-approved-for-multiple-myeloma 2021-04-14T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/nccn-announces-projects-to-study-oral-decitabine-and-cedazuridine 2021-04-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nccn-announces-projects-to-study-oral-decitabine-and-cedazuridine 2021-04-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/bispecific-car-t-therapy-targeting-cd19-cd20-shows-promise-in-relapsed-b-cell-lymphoma 2021-04-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bispecific-car-t-therapy-targeting-cd19-cd20-shows-promise-in-relapsed-b-cell-lymphoma 2021-04-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/mayo-clinic-study-links-car-t-cell-aging-to-cancer-relapse-in-largest-b-cell-lymphoma-analysis 2021-04-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mayo-clinic-study-links-car-t-cell-aging-to-cancer-relapse-in-largest-b-cell-lymphoma-analysis 2021-04-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/neoadjuvant-chemohormonal-therapy-before-radical-prostatectomy-for-high-risk-prostate-cancer 2021-04-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neoadjuvant-chemohormonal-therapy-before-radical-prostatectomy-for-high-risk-prostate-cancer 2021-04-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ema-grants-orphan-drug-designation-to-ict01-for-acute-myeloid-leukemia-treatment 2021-04-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ema-grants-orphan-drug-designation-to-ict01-for-acute-myeloid-leukemia-treatment 2021-04-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/pfizer-s-sasanlimab-bcg-combination-shows-significant-improvement-in-high-risk-bladder-cancer-trial 2021-04-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pfizer-s-sasanlimab-bcg-combination-shows-significant-improvement-in-high-risk-bladder-cancer-trial 2021-04-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/controversy-surrounds-fda-approval-of-pembrolizumab-for-high-tmb-solid-tumors 2021-04-08T15:00:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/controversy-surrounds-fda-approval-of-pembrolizumab-for-high-tmb-solid-tumors 2021-04-08T15:00:04+00:00 weekly 0.7 https://trial.medpath.com/news/prostate-specific-membrane-antigen-psma-targeted 2021-03-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/prostate-specific-membrane-antigen-psma-targeted 2021-03-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/adr-that-result-in-revision-of-patient-information-2021-03-25-1 2021-03-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/adr-that-result-in-revision-of-patient-information-2021-03-25-1 2021-03-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/uk-pm-s-greed-comments-spark-controversy-amid-global-vaccine-distribution-debate 2021-03-23T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/uk-pm-s-greed-comments-spark-controversy-amid-global-vaccine-distribution-debate 2021-03-23T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/gamification-emerges-as-powerful-tool-in-healthcare-from-patient-care-to-medical-education 2021-03-22T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gamification-emerges-as-powerful-tool-in-healthcare-from-patient-care-to-medical-education 2021-03-22T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cdk4-6-inhibitors-as-adjuvant-treatment-for-hormone-receptor-positive-her2-negative-early-breast-cancer-a-meta-analysis 2021-03-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cdk4-6-inhibitors-as-adjuvant-treatment-for-hormone-receptor-positive-her2-negative-early-breast-cancer-a-meta-analysis 2021-03-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/savana-leverages-ai-to-transform-ehr-data-into-actionable-clinical-insights 2021-03-15T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/savana-leverages-ai-to-transform-ehr-data-into-actionable-clinical-insights 2021-03-15T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/phase-3-trial-of-libtayo-r-cemiplimab-monotherapy-in-advanced-cervical-cancer-shows-significant-survival-benefit 2021-03-15T02:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-3-trial-of-libtayo-r-cemiplimab-monotherapy-in-advanced-cervical-cancer-shows-significant-survival-benefit 2021-03-15T02:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/advances-in-prognostication-and-treatment-of-polycythemia-vera-with-pegylated-interferon-and-mdm2-inhibition 2021-03-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/advances-in-prognostication-and-treatment-of-polycythemia-vera-with-pegylated-interferon-and-mdm2-inhibition 2021-03-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/virtual-patient-engagement-reshapes-clinical-trial-design-post-covid 2021-03-11T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/virtual-patient-engagement-reshapes-clinical-trial-design-post-covid 2021-03-11T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/study-demonstrates-effectiveness-of-precision-biopsy-strategy-in-prostate-cancer-detection 2021-03-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-demonstrates-effectiveness-of-precision-biopsy-strategy-in-prostate-cancer-detection 2021-03-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/mrna-covid-19-vaccines-achieve-historic-emergency-authorization-with-95-efficacy 2021-03-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mrna-covid-19-vaccines-achieve-historic-emergency-authorization-with-95-efficacy 2021-03-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/metastatic-patterns-and-treatment-response-in-prostate-cancer-new-insights-into-disease-progression 2021-03-03T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/metastatic-patterns-and-treatment-response-in-prostate-cancer-new-insights-into-disease-progression 2021-03-03T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/lyme-prep-novel-monoclonal-antibody-treatment-enters-human-clinical-trials 2021-03-03T08:45:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lyme-prep-novel-monoclonal-antibody-treatment-enters-human-clinical-trials 2021-03-03T08:45:00+00:00 weekly 0.7 https://trial.medpath.com/news/research-initiative-launches-to-address-mental-health-crisis-in-rare-disease-diagnoses 2021-02-25T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/research-initiative-launches-to-address-mental-health-crisis-in-rare-disease-diagnoses 2021-02-25T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-gene-therapy-eliminates-need-for-enzyme-replacement-in-fabry-disease-patients 2021-02-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/breakthrough-gene-therapy-eliminates-need-for-enzyme-replacement-in-fabry-disease-patients 2021-02-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/new-video-resource-highlights-critical-insights-from-rare-disease-patient-community 2021-02-24T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-video-resource-highlights-critical-insights-from-rare-disease-patient-community 2021-02-24T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/off-the-shelf-nk-immunotherapy-shows-promise-in-b-cell-nhl-treatment 2021-02-19T17:00:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/off-the-shelf-nk-immunotherapy-shows-promise-in-b-cell-nhl-treatment 2021-02-19T17:00:19+00:00 weekly 0.7 https://trial.medpath.com/news/a-reflection-on-the-covid-19-vaccine 2021-02-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-reflection-on-the-covid-19-vaccine 2021-02-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/grunenthal-leaders-outline-four-key-principles-for-future-pharmaceutical-marketing-in-post-covid-era 2021-02-15T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/grunenthal-leaders-outline-four-key-principles-for-future-pharmaceutical-marketing-in-post-covid-era 2021-02-15T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/semaglutide-shows-unprecedented-weight-loss-results-in-major-international-trial 2021-02-11T21:22:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/semaglutide-shows-unprecedented-weight-loss-results-in-major-international-trial 2021-02-11T21:22:27+00:00 weekly 0.7 https://trial.medpath.com/news/ipsen-advances-neurotoxin-research-for-spasticity-treatment-aims-to-develop-longer-acting-therapies 2021-02-11T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ipsen-advances-neurotoxin-research-for-spasticity-treatment-aims-to-develop-longer-acting-therapies 2021-02-11T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/heart-disease-devices-lead-latest-batch-of-fda-breakthrough-nods 2021-02-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/heart-disease-devices-lead-latest-batch-of-fda-breakthrough-nods 2021-02-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-prucalopride-for-chronic-idiopathic-constipation 2021-02-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-prucalopride-for-chronic-idiopathic-constipation 2021-02-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/jazz-pharmaceuticals-acquires-gw-pharma-in-7-2b-cannabis-medicine-deal 2021-02-03T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/jazz-pharmaceuticals-acquires-gw-pharma-in-7-2b-cannabis-medicine-deal 2021-02-03T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/disease-rarity-and-clinical-benefits-drive-rare-disease-drug-pricing-in-germany-s-amnog-system 2021-02-01T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/disease-rarity-and-clinical-benefits-drive-rare-disease-drug-pricing-in-germany-s-amnog-system 2021-02-01T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/bms-seeks-fda-approval-for-zeposia-in-ulcerative-colitis-with-may-decision-date 2021-02-01T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bms-seeks-fda-approval-for-zeposia-in-ulcerative-colitis-with-may-decision-date 2021-02-01T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/promising-results-for-ziresovir-in-treating-respiratory-syncytial-virus-in-infants 2021-02-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/promising-results-for-ziresovir-in-treating-respiratory-syncytial-virus-in-infants 2021-02-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/medtronic-receives-fda-approval-of-diamondtemp-ablation-system-for-the-treatment-of-patients-with-atrial-fibrillation 2021-01-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/medtronic-receives-fda-approval-of-diamondtemp-ablation-system-for-the-treatment-of-patients-with-atrial-fibrillation 2021-01-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/sangamo-therapeutics-charts-pragmatic-course-in-gene-editing-evolution-balancing-innovation-with-viability 2021-01-28T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sangamo-therapeutics-charts-pragmatic-course-in-gene-editing-evolution-balancing-innovation-with-viability 2021-01-28T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/us-biosimilar-market-set-for-100-billion-cost-reduction-as-adoption-accelerates 2021-01-27T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/us-biosimilar-market-set-for-100-billion-cost-reduction-as-adoption-accelerates 2021-01-27T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/rising-liver-cancer-cases-in-the-us-linked-to-alcohol-associated-liver-disease-and-masld 2021-01-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rising-liver-cancer-cases-in-the-us-linked-to-alcohol-associated-liver-disease-and-masld 2021-01-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/addressing-the-trust-crisis-in-clinical-trials-lessons-from-historical-cases-to-modern-solutions 2021-01-26T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/addressing-the-trust-crisis-in-clinical-trials-lessons-from-historical-cases-to-modern-solutions 2021-01-26T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-breakthrough-device-designation-granted-for 2021-01-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-breakthrough-device-designation-granted-for 2021-01-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/leading-biotech-companies-converge-at-mitochondria-targeted-drug-development-summit-to-advance-therapeutic-pipeline 2021-01-24T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/leading-biotech-companies-converge-at-mitochondria-targeted-drug-development-summit-to-advance-therapeutic-pipeline 2021-01-24T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/five-year-outcomes-from-the-randomized-phase-iii-trials-nivolumab-versus-docetaxel-in-previously-treated-non-small-cell-lung-cancer 2021-01-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/five-year-outcomes-from-the-randomized-phase-iii-trials-nivolumab-versus-docetaxel-in-previously-treated-non-small-cell-lung-cancer 2021-01-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/recurrent-gbm-brain-tumors-with-few-mutations-respond-best-to-immunotherapy 2021-01-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/recurrent-gbm-brain-tumors-with-few-mutations-respond-best-to-immunotherapy 2021-01-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/uk-launches-new-pathways-for-accelerated-drug-access-and-evaluation-in-2021 2021-01-11T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/uk-launches-new-pathways-for-accelerated-drug-access-and-evaluation-in-2021 2021-01-11T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/bluebird-bio-announces-strategic-split-into-separate-gene-therapy-and-oncology-companies 2021-01-10T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bluebird-bio-announces-strategic-split-into-separate-gene-therapy-and-oncology-companies 2021-01-10T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-novartis-scemblix-r-asciminib-with-novel-mechanism 2021-01-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-novartis-scemblix-r-asciminib-with-novel-mechanism 2021-01-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/innovative-car-t-cell-and-oncolytic-virus-therapies-show-promise-in-treating-aggressive-cancers 2021-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/innovative-car-t-cell-and-oncolytic-virus-therapies-show-promise-in-treating-aggressive-cancers 2021-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/triplet-combination-of-durvalumab-tremelimumab-and 2021-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/triplet-combination-of-durvalumab-tremelimumab-and 2021-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-design-during-and-beyond-the-pandemic 2021-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-trial-design-during-and-beyond-the-pandemic 2021-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/biomarkers-identified-for-camrelizumab-apatinib-combination-in-advanced-triple-negative-breast-cancer 2021-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biomarkers-identified-for-camrelizumab-apatinib-combination-in-advanced-triple-negative-breast-cancer 2021-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/role-of-immunotherapy-in-bladder-cancer 2021-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/role-of-immunotherapy-in-bladder-cancer 2021-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/rakuten-medical-acquires-critical-irdye-700dx-assets-from-li-cor-to-secure-photoimmunotherapy-supply-chain 2020-12-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rakuten-medical-acquires-critical-irdye-700dx-assets-from-li-cor-to-secure-photoimmunotherapy-supply-chain 2020-12-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/covid-19-pandemic-reshapes-patient-centric-clinical-trial-landscape-in-2020 2020-12-21T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/covid-19-pandemic-reshapes-patient-centric-clinical-trial-landscape-in-2020 2020-12-21T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/palforzia-a-new-hope-for-children-with-peanut-allergy 2020-12-21T12:02:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/palforzia-a-new-hope-for-children-with-peanut-allergy 2020-12-21T12:02:00+00:00 weekly 0.7 https://trial.medpath.com/news/interferon-alpha-shows-promise-in-reducing-myelofibrosis-risk-and-mortality-in-polycythemia-vera-patients 2020-12-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/interferon-alpha-shows-promise-in-reducing-myelofibrosis-risk-and-mortality-in-polycythemia-vera-patients 2020-12-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/dr-patnaik-on-activity-of-sl-401-in-chronic 2020-12-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dr-patnaik-on-activity-of-sl-401-in-chronic 2020-12-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/sglt2-inhibitors-show-promising-results-for-elderly-with-type-2-diabetes 2020-12-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sglt2-inhibitors-show-promising-results-for-elderly-with-type-2-diabetes 2020-12-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/how-the-clinical-research-community-responded-to-the-covid-19 2020-12-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/how-the-clinical-research-community-responded-to-the-covid-19 2020-12-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/enhertu-nears-eu-approval-for-her2-positive-breast-cancer-treatment 2020-12-13T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/enhertu-nears-eu-approval-for-her2-positive-breast-cancer-treatment 2020-12-13T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/scottish-health-authority-rejects-daiichi-sankyo-s-novel-cholesterol-drug-nilemdo 2020-12-07T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/scottish-health-authority-rejects-daiichi-sankyo-s-novel-cholesterol-drug-nilemdo 2020-12-07T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/3030-preliminary-results-of-an-ongoing-phase-1-dose 2020-12-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/3030-preliminary-results-of-an-ongoing-phase-1-dose 2020-12-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/uniqure-announces-two-year-follow-up-data-from-the-phase-iib-study-of-etranacogene-dezaparvovec 2020-12-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/uniqure-announces-two-year-follow-up-data-from-the-phase-iib-study-of-etranacogene-dezaparvovec 2020-12-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/navigating-latin-american-pharma-markets-challenges-and-opportunities-amid-regulatory-evolution 2020-12-06T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/navigating-latin-american-pharma-markets-challenges-and-opportunities-amid-regulatory-evolution 2020-12-06T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/mrna-vaccines-how-moderna-and-pfizer-biontech-revolutionized-covid-19-immunization 2020-12-05T18:35:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mrna-vaccines-how-moderna-and-pfizer-biontech-revolutionized-covid-19-immunization 2020-12-05T18:35:42+00:00 weekly 0.7 https://trial.medpath.com/news/reporting-and-design-of-randomized-controlled-trials-for-covid-19 2020-12-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/reporting-and-design-of-randomized-controlled-trials-for-covid-19 2020-12-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-fast-track-designation-for-remestemcel-l-in-the-treatment-of 2020-12-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-fast-track-designation-for-remestemcel-l-in-the-treatment-of 2020-12-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/gout-drug-colchicine-to-be-tested-as-covid-19-treatment-daily-mail-online 2020-11-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gout-drug-colchicine-to-be-tested-as-covid-19-treatment-daily-mail-online 2020-11-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/technological-advances-and-patient-partnerships-drive-new-era-in-rare-disease-drug-development 2020-11-26T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/technological-advances-and-patient-partnerships-drive-new-era-in-rare-disease-drug-development 2020-11-26T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/significant-improvement-in-progression-free-survival-with-sarclisa-combination-therapy-for-previously-treated-multiple-myeloma 2020-11-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/significant-improvement-in-progression-free-survival-with-sarclisa-combination-therapy-for-previously-treated-multiple-myeloma 2020-11-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/gilead-s-27-billion-oncology-transformation-strategic-deals-reshape-company-s-future 2020-11-23T23:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gilead-s-27-billion-oncology-transformation-strategic-deals-reshape-company-s-future 2020-11-23T23:00:00+00:00 weekly 0.7